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Lactate has long been considered a "waste"-by-product of cellular metabolism, and 
it is known to accumulate in inflammatory sites. Recent findings have suggested 
lactate as signaling metabolite, yet its effects on immune cells during inflammation 
are largely unexplored. This project hence aimed to examine the effects of 
extracellular lactate on the function of T cells. 
 
I found that the elevated concentration of lactate present in synovia of rheumatoid 
arthritis (RA) patients inhibits the migration of CD4+ and CD8+ T cells, mediated via 
the subtype specific transporters Slc5a12 and Slc16a1, respectively. In addition, 
lactate decreases the cytolytic activity in CD8+ and induces the production of IL-17 
in CD4+ T cells. 
 
Intracellular, lactate causes a change in redox state, the increase of TCA-cycle 
metabolites, the production of ROS and a drop in ATP levels. Concomitantly, I found 
a decrease of glycolysis and oxidative phosphorylation with no effect on fatty acid 
metabolism. This metabolic inhibition caused an adaptation attempt to rescue the 
glycolytic flux due to the relocation of HK1 to the mitochondrial membrane. 
 
I further show that the lactate-mediated reduction of glycolysis is the cause for the 
observed migratory inhibition in CD4+ T cells, possibly mediated by the NAD+-
dependent enzymes SIRT1 and PARP1. Similarly, I found the lactate-induced IL-17 
production to be dependent on NAD metabolism, fatty acid synthesis and FOXO1. 
 
Finally, I could causatively link lactate signaling to chronic T cell infiltrates in RA, as 
I show that the expression of lactate transporters correlates with the clinical T cell 
score in the synovia of RA patients. Pharmacological or antibody-mediated blockade 
of subtype-specific lactate transporters on T cells results in their release from the 
inflammatory site in a model of peritonitis. 
 
These findings establish lactate as active signaling metabolite that contributes to 
the perpetuation of chronic inflammation and provide novel therapeutic approaches 
to combat chronic inflammatory diseases. 
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2.1 BASIC ASPECTS OF T CELL MEDIATED IMMUNITY 
	  
2.1.1 The constituents of the immune system 
 
The immune system consists of a highly complex network of specialized cells 
working together to prevent infiltrating viruses and microbes from spreading and 
thus protecting the body against external pathogens. It can be divided into two 
main arms, namely the innate and the adaptive immune systems, both fulfilling 
specific exclusive functions that complement each other to provide the body with 
optimal protection. Innate immunity delivers broad, non-specific and immediate 
defense against invading microbes, yet the timeframe of protection is only limited. 
The adaptive immune response on the other hand is delayed, yet highly specific for 
the invading pathogen and offers long lasting protection in case of re-infection. 
Below I will describe in more detail the innate and adaptive defense mechanism of 
immunity (Murphy, 2011). 
 
2.1.2 The innate immune system 
 
Innate immunity is the evolutionary older arm of the immune system, which 
developed over 600 million years ago and can be found in ‘representative species in 
almost every level of the evolutionary tree of life’ (Cooper and Herrin, 2010). It 
represents the first line of defense against pathogens acting on several levels that 
reach from physical barriers to phagocytic engulfment and pathogen clearance by 
highly specialized phagocytes. Epithelial cells line as physical barriers the entire 
surface of the human body including the internal lumen of the gut and respiratory 
tract, generating an isolated environment that is protected from external insults. 
Beneath this protective barrier tissue resident macrophages and dendritic cells 
reside that play a pivotal role in host defense and activation of the inflammatory 
cascade (Murphy, 2011). Their importance becomes clear in the case of tissue 
disruption such as a wound or in an infection that enables a microbe to overcome 
the epithelial barrier and enter the body.  
 
2.1.2.1 Pattern Recognition 
 
Immune detection of pathogens is achieved via specialized surface receptors on 
immune cells called pattern recognition receptors (PRR) that detect microbial 
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pathogen associated molecular patterns (PAMPs) (Medzhitov and Janeway, 2000). 
It was this groundbreaking finding of PRRs that explained the basic functionality of 
innate immune detection and the striking difference to adaptive immune activation. 
The mammalian homologs of drosophila Toll-like receptors (TLR) detect specialized 
patterns and structures on the surface of microbes. Next to TLR4 that recognizes 
the gram-negative Lipopolysaccharide (LPS), which was one of the first TLRs 
discovered, several others have been described, each of them specialized for a 




Inflammation describes the tissue infiltration by activated immune cells that can be 
initiated by either the detection of an intruding microbe or tissue injury (Medzhitov, 
2008). Tissue resident macrophages respond to stimuli such as lipopolysaccharide 
(LPS) with activation and subsequent release of pro-inflammatory signals including 
cytokines and chemokines (Haschemi et al., 2012). These soluble inflammatory 
mediators in turn attract other immune cells and regulate the inflammatory 
response in order to clear the infection or restore tissue homeostasis (Ahsley, 
2012). According to (Medzhitov, 2008) inflammation can be triggered by several 
stimuli and depending on the type of trigger there will be different physiological and 
pathological consequences (Figure I). 
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Figure I Origins of chronic inflammation (Medzhitov, 2008) 
Different physiological or pathological triggers can cause inflammation that have a specific physiologic 
purpose and can lead to the development of diseases (pathological consequences). 
	  
	  
In acute inflammation, pathogen clearance and tissue repair lead to the resolution 
of inflammation and the reestablishment of homeostasis that is mediated by several 
factors in the inflammatory site (Ortega-Gomez et al., 2013). Failure to restore 
tissue homeostasis leads to the perpetuation of inflammation to a chronic state that 
contributes to the establishment of chronic inflammatory and autoimmune diseases 
such as atherosclerosis, rheumatoid arthritis or cancer. This issue will be discussed 
in a later chapter. 
The initiation of the acute inflammatory cascade activates and attracts several 
innate immune cells such as neutrophils, eosinophils or basophils and monocytes, 
which differentiate into macrophages once inside the tissue. These granulocytes 
and phagocytes respectively efficiently clear microbial infections with the release of 
reactive oxygen species, cytolytic granules and the engulfment of cellular debris, 
called phagocytosis. As soon as the infection is cleared, anti-inflammatory and 
inflammation resolving factors, such as Annexin A1 (AnxA1), are released that lead 
to the resolution of ongoing inflammation and to the reestablishment of 
homeostasis (Corminboeuf and Leroy, 2014). Although the innate immune system 
is a firm clearer of microbial infections, it delivers only broad, unspecific and short 
lasting defense. In order to provide the body with immunity against reoccurring 
infections a more specific and effective type of immune response has evolved – 
adaptive immunity. 
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2.1.3 The adaptive immune system 
 
The adaptive immune system is a specialized arm of immunity that protects the 
body efficiently from reoccurring infections in an antigen-specific manner. In 
contrast to the innate part of the immune system, adaptive immune cells comprise 
only two types, namely B and T cells. For B and T cells to get activated and fulfill 
their effector functions antigen presentation has to occur (Guermonprez et al., 
2002). As the primary focus of this report and work is on T cells, only antigen 
presentation to this cell type will be discussed below. 
 
2.1.3.1 Antigen encounter and presentation 
 
Primary antigen encounter happens in the periphery where highly specialized 
antigen presenting cells (APCs) pick up an antigen and start processing it for 
presentation to the lymphocytes. Only a few professional APCs have been identified 
so far, including dendritic cells (DC), macrophages and B cells (Guermonprez et al., 
2002). Although even T cells have been implicated to function as APCs (Pichler and 
Wyss-Coray, 1994), only DCs are broadly recognized as the main antigen 
presenting cell type in the body.  
 
DCs are found in unique locations throughout the body allowing them to efficiently 
acquire antigen. Positioned on the body’s surface areas, such as the skin, pharynx, 
upper oesphagus, vagina, ectocervix and anus as well as in mucosal surfaces 
including the gastrointestinal and respiratory tract, DCs inhabit the areas where 
they are most likely to come in contact with antigen (Steinman and Banchereau, 
2007). Once the DC ‘senses’ the presence of pathogen material, it uses surface 
scavenger receptors to bind and internalize the antigen. Many scavenger receptors 
are lectins with a carbohydrate recognition element that enables them to recognize 
and internalize bacterial- or viral-derived antigens (Steinman and Banchereau, 
2007). Other ways of antigen uptake include phagocytosis of microbes or particles 
and macropinocytosis, which constitute the formation of large pinocytic vesicles 
containing extracellular fluid and other solutes (Sallusto et al., 1995). These three 
ways of antigen encounter make the DC such an effective APC and make it possible 
that pico- and nanomolar concentrations of antigen suffice for efficient antigen 
presentation (Banchereau and Steinman, 1998). 
 
Once the antigen has been engulfed, it undergoes a complex processing route 
inside the DC to finally get presented in the form of short peptides bound to Major 
Histocompatibility Complex (MHC) class I or class II molecules to the lymphocytes 
in the secondary lymphoid organs (SLO) (Neefjes et al., 2011). Alongside with 
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antigen processing, the DC starts to mature and migrate to the lymph nodes where 
it effectively presents the processed antigen to T and B cells and initiate clonal 
expansion and the onset of the adaptive immune response. 
 
The migration of DCs occurs in a similar manner to lymphocytes, which will be 
discussed in more detail in a later chapter. Murine DCs are characterized by the 
expression of CD11c surface marker, yet many different subsets with various 
surface receptor expression profiles have been described (Merad et al., 2013). 
Depending on the subsets of DC the way of entry into the LN differs, including DCs 
entering from the blood (del Hoyo et al., 2002) as well as DCs entering through the 
afferent lymphatic vessel (Anjuere et al., 1999; Ruedl et al., 2000). The actual 
antigen presentation to naïve T lymphocytes occurs in the cortex of the LN and 
requires the physical contact between a DC and the naïve T cell.  
 
(Mempel et al., 2004) could show, using two-photon microscopy, that T cell priming 
occurs in three distinct phases, consisting of short T cell-DC interactions that result 
in decrease of T cell motility and upregulation of activation markers. Following, T 
cells and DCs form stable conjugates lasting for 12 hours and leading to the 
production of interferon gamma (IFNγ) and interleukin-2 (IL-2). In the last phase T 
cells regain their high motility characteristics and resume with the initial short 
interactions with DCs. The third phase of T cell priming also coincides with the 
onset of T cell proliferation and clonal expansion, characteristic of the adaptive 
immune response (Mempel et al., 2004). As can be seen, T cell priming depends on 
physical interaction of antigen-MHC complex on the DC with the T cell receptor 
(TCR) on the naïve T cell. In order to yield a potent T cell immune response that 
relies on clonal expansion of the primed T cell, several other signals are necessary 
to ensure the correctness of the reaction and to avoid inappropriate activation to 
false signals. The next chapter will describe in more detail T cell activation and the 
connected proliferative clonal expansion that yields the highly specific antigen 
dependent immune response. 
 
2.1.3.2 T Cell Activation & Proliferation 
 
The activation of T cells describes the biochemical and morphological events that 
occur in the naïve T cell after peptide MHC recognition (Smith-Garvin et al., 2009). 
In recent years the importance of metabolic adaption during immune cell activation 
has been thoroughly investigated and will be discussed in a later chapter. Below I 
will describe the downstream signaling cascade that is initiated upon antigen 
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presentation to the T cell receptor (TCR) and the phenotypical characteristics that 
change subsequently and lead to T cell activation. 
 
2.1.3.2.1 T Cell Receptor Signaling 
 
Responsible for the recognition of peptide MHC complexes by naïve T cells is the 
TCR, an integral and defining molecule on the T cell surface. The TCR is a 
heterodimer consisting of an α- and β-chain that are each anchored to the cell 
membrane and in complex with the signaling molecule CD3 (Weiss and Stobo, 
1984). Although the majority of T cells express the α- and β-chain, in about 5% of 
T cells these are replaced by a γ- and δ-chain. While the composition of the TCR is 
an exciting area of research that has important disease implications (Vantourout 
and Hayday, 2013), it will not be further discussed here. 
 
The TCR signaling cascade involves a series of adaptor and effector molecules that 
act together to constitute the TCR complex and effectively transduce signals (Figure 
II) upon interaction with the antigen - MHC complex. The first experimental 
investigations into TCR signaling could demonstrate a rise in intracellular Ca2+ 
levels in response to phorbol esters and Ca2+ ionophores. This release of Ca2+ into 
the cytosol originated from intracellular pools mediated by inositol triphosphate 
(IP3) that coincided with Ca2+ influx from the extracellular space (Imboden et al., 
1985). Subsequent studies identified Phospholipase C (PLC) as downstream effector 
enzyme of the TCR, generating IP3 and Diacylglycerol (DAG) from the hydrolysis of 
the membrane bound phospholipid inositol 4,5 bisphosphate, which are responsible 
for Ca2+ release (Smith-Garvin et al., 2009). 
 
While these studies have delivered immense contribution to the understanding of 
the TCR cascade the detailed mechanisms of how the TCR conveyed the signal from 
the interaction with the antigen-MHC complex remained obscure. It is now clear 
that one of the earliest events after TCR ligation to the MHC is the phosphorylation 
of immunoreceptor tyrosine based activation motifs (ITAM) on the cytosolic side of 
the CD3 ζ-chain mediated by lymphocyte protein tyrosine kinase (Lck). This 
phosphorylation triggers a chain of events including the recruitment and activation 
of ζ-chain associated protein kinase (Zap70), which in turn promotes the 
recruitment of the adaptor proteins Slp-76, Vav, NCK, GADS and inducible T cell 
kinase (Itk). This complex is then able to phosphorylate the previously mentioned 
PLC and activate Ca2+ signaling. 
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Figure II T cell receptor signaling (Xiang et al., 2010) 
Upon antigen recognition, the T cell receptor delays the signal via adaptor molecules and downstream 




The activation of naïve T cells is a complex process that requires not only the TCR 
signal, but also the stimulation of several other costimulatory receptors (Chen and 
Flies, 2013). CD28 has been shown to be essential for proper T cell activation as its 
absence induces T cell anergy (Okkenhaug et al., 2001; Schwartz, 1990) and 
anergic T cells were found to have defective CD28 signaling (Suzuki et al., 1995). 
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The triggering of CD28 signaling requires binding of one of its ligands CD80 (B7.1) 
or CD86 (B7.2) that are expressed on activated DCs. Interestingly initiation of 
CD28 signaling through either CD80 or CD86 has been shown to be highly 
redundant as they lead to the same downstream biochemical effects in the 
activation phase (Acuto and Michel, 2003). The importance of CD28 signaling 
activation in TCR stimulation has been widely explained by the fact that it lowers 
the threshold for TCR activation and increases the response duration that in turn 
leads to stabilized expression of IL-2, which favors T cell survival (Rudd, 1996). The 
interaction between CD28 and its ligands leads to the phosphorylation of the 
cytoplasmatic domain of CD28 and subsequent recruitment of PI3K, which has wide 
reaching effects on T cell fate and function. T cell receptor activation and 
downstream signaling lead to dramatic changes in gene expression levels, 
metabolic activity and macromolecule synthesis. This, in turn, enables the T cell to 
alter its morphology, grow and start to proliferate. 
 
2.1.3.2.2 Phenotypical Changes during Activation 
 
Upon activation of the TCR signaling cascade, the T cell undergoes a plethora of 
phenotypical and morphological changes that enable it to mount an appropriate 
adaptive immune response. Naïve T cells are characterized by surface expression of 
CCR7, L-Selectin (CD62L) and the IL-7R (CD127) that enable them to effectively 
patrol secondary lymphoid organs and scan for peptide:MHC complexes for their 
cognate antigen. During the first 12h after antigen recognition the naïve T cells 
grows in size, starts to produce cytokines including IL-2, IL-4 and IFNγ and 
acquires an activated surface phenotype by expressing the surface markers CD25, 
CD44 and CD69. After this initial growth phase, the clonal expansion phase begins 
in which the T cell starts actively to proliferate (Ley, 2014; Mempel et al., 2004). 
After successful activation and proliferation, activated T cells start egressing the 
lymph nodes and travel towards the site of inflammation. 
 
2.1.3.3 T Cell Trafficking 
 
Naïve T cells patrol continuously throughout the lymphatic system and home to 
SLO’s in order to increase the likelihood of successful antigen encounter and 
initiation of a proper adaptive immune response (Takada and Jameson, 2009). The 
main route of T lymphocyte entry to SLO’s is via High Endothelial Venules (HEV), 
which represents a highly efficient way of lymph node entry (Mackay et al., 1990; 
von Andrian and Mempel, 2003). Lymphocyte trafficking and entry into SLO’s or 
target tissue generally involves four different subsequent steps, including tethering, 
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rolling, activation and arrest (Marelli-Berg et al., 2008). Naïve lymphocytes first 
initiate tethering to endothelial cells via an interaction between leukocyte receptor 
L-selectin (CD62L) and its endothelial ligand PNAd – an O-linked carbohydrate 
moiety, expressed on HEV’s. This interaction leads to subsequent rolling on the 
endothelial surface, mediated by L-selectin and PNAd interactions. Subsequently, 
firm arrest of T cell rolling is facilitated by the integrin Leukocyte Function-
associated Antigen 1 (LFA-1) that interacts with endothelial inter-cellular adhesion 
molecule 1 (ICAM 1), which allows for transmigration into the lymph node (Figure 
III) (von Andrian and Mempel, 2003). 
 
	  
Figure III Lymphocyte tethering, rolling and arrest on HEVs (von Andrian 
and Mempel, 2003)) 
Leukocytes enter the SLO’s or target tissue via a four-step cascade including tethering to and rolling on 
the endothelial surface, firm adhesion and finally transmigration through the endothelial layer. 
 
 
Efficient leukocyte arrest requires the activation of integrins (i.e. LFA1). This occurs 
via the chemokine receptor CCR7 binding to its ligands CCL19 or CCL21, which are 
expressed on the surface of HEVs (Marelli-Berg et al., 2008). Although LFA1 can 
bind both ligands, the relative contribution of CCL19 and CCL21 to leukocyte arrest 
remains to be determined. Both chemokines are also highly expressed in the T cell 
zone of the paracortex in the lymph node, in which they increase T cell motility and 
are believed to maximize antigen-scanning on DCs (Masopust and Schenkel, 2013). 
It has been estimated that one DC is ‘scanned’ by up to 500 T cells per hour 
(Bousso and Robey, 2003). 
 
T cell activation induces the up-regulation of several activation markers, including 
the hyaluronic acid receptor CD44, a glycoprotein that has been described to define 
an effector memory phenotype (Yamaki et al., 2014). Interestingly, CD44 deficient 
mice show normal embryonic and lymphocyte development, yet the homing 
patterns including the entry into the thymus especially are defective (Protin et al., 
1999). Other activation markers include CD25, the alpha chain of the IL-2 receptor 
and CD69, a C-type lectin protein involved in T cell proliferation (Lauzurica et al., 
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2000), which becomes highly expressed during activation. In parallel with these 
activation markers, the expression pattern of chemokine receptors changes during 
activation. In contrast to naïve T cells that express CCR7 and L-selectin, allowing 
efficient homing and entry into the lymph node, T cell activation leads to increased 
expression of receptors that allow T cell access to non-lymphoid tissue, including 
the integrins LFA-1 and VLA-4 and chemokine receptors such as CCR5 and CXCR3 
on the Th1 subset, CCR4 and Crth2 on the type 2 helper subset as well as CCR6 on 
the Th17 subset (Islam and Luster, 2012). 
 
After antigen encounter and successful activation and proliferation, T cells egress 
from the lymph node and start to travel to the site of inflammation. This egress is 
mediated by a sphingosine-1-phosphate (S1P) – S1P receptor (S1PR) signaling 
cascade that allows the entry of a T cell into a cortical sinus within the lymph node, 
hereby paving the way for efficient exit through efferent lymphatics (Pappu et al., 
2007). Interestingly, it was shown that S1PR acts mainly to overcome the 
competitive CCR7 signaling on the T cell, which promotes the retention in the 
lymph node (Pham et al., 2008). 
 
Directed migration into the inflamed tissue is mostly orchestrated by pro-
inflammatory chemokines that are mainly secreted by endothelial cells surrounding 
the inflammatory site (Nourshargh, 2014), exposed to pro-inflammatory cytokines 
such as TNFα (Harris et al., 2014). Details of chemokine signaling are described in 
the next section. 
 
2.1.3.4 Chemokine Signaling 
 
On their way throughout the body, T cells are guided by a family of small chemo-
attractant lipid or protein molecules called chemokines that initiate migratory 
chemotactic response upon binding to a chemokine receptor on the cell surface 
(Ward, 2006). Protein chemokines are structurally classified into the four groups C, 
CC, CXC and CX3C, due to the number and spacing of their N-terminal cysteine 
residues (Curnock et al., 2002). Directional, chemokine-mediated T cell trafficking 
is a complex process that involves ligand redundancy, collaboration and antagonism 
in addition to the emerging concept of biased receptor signaling in which 
structurally unrelated chemokines activate different downstream signaling 
pathways from the same receptor (Groom and Luster, 2011; Zweemer et al., 
2014). 
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The signal transduction cascade is mediated via binding of chemokines to a seven 
transmembrane receptor, coupled to a G-protein (GPCR) that activates a variety of 
downstream effector molecules, ultimately leading to cytoskeletal reorganization 
and cell polarization (Mellado et al., 2001). Binding of the chemokine follows a 
conformational change in the receptor that causes the dissociation of Gβγ subunit 
and the Guanosin Triphosphate (GTP) bound Gαi subunit of the G-protein (Figure 
IV). Gβγ activates Phospholipase C (PLC) that leads to the formation of 
Diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn causes the 
release of Ca2+ from the endoplasmatic reticulum (ER). DAG and Ca2+ then act in 
concert to activate protein kinase C (PKC) and several downstream effector kinases 
(Mellado et al., 2001). 
 
	  
Figure IV Chemokine receptor signaling in T cells (Patel et al., 2013) 
The binding of a chemoattractant protein to a chemokine receptor triggers the activation of the attached 
G protein via dissociation of the βγ subunit from the Gα subunit. Both Gα and βγ activate a variety of 
downstream effector molecules that lead to the induction of second messenger molecules. 
 
Another class of enzymes that can be activated upon GPCR signaling is the family of 
phosphoinositide 3 Kinases (PI3K), which represent a central effector molecule in a 
cell’s response to a chemokine (Curnock et al., 2002). PI3K phosphorylates IP3 to 
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generate the two signaling molecules PIP2 (Phosphatidylinositol 3,4-Bisphosphate) 
and PIP3 (Phosphatidylinositol 3,4,5-Trisphosphate) that in turn can activate 
several protein kinases by binding to their pleckstrin homology (PH) domains 
(Cantley, 2002). 
 
The activation of PI3K is an indispensable event for T cell chemotaxis, yet it seems 
not to be necessary for directional migration (Cronshaw et al., 2004; Smit et al., 
2003). Besides the predominant lipid kinase activity of PI3K, which leads to the 
phosphorylation of phosphoinositides, PI3K also has direct protein kinase activity 
and a large array of downstream targets (Thomas et al., 2013). The best-described 
target of PI3K is the serine / threonine kinase Akt (PKB), which has been shown to 
be activated by a variety of chemokines including CCL5, IL-8 and CXCL12 (Curnock 
et al., 2002). The protein kinase Akt (PKB) is a major signaling hub that is involved 
in the response to cytokines, growth factors and intracellular stimuli and regulates 
a plethora of cellular outcomes including survival, growth, angiogenesis, 
proliferation, metabolism and non-the last migration (Manning and Cantley, 2007). 
 
 
Although key features of T cell mediated immunity have been known for some time, 
the biochemical aspects of T cell function and migration have only recently come 
into focus. As it turns out, biochemistry plays a fundamental role in every part of T 
cell activation and effector function, as will be described in the next section. 
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2.2 THE BIOCHEMISTRY OF T CELL FUNCTION 
 
2.2.1 Metabolic Adaption during T cell Activation 
 
The biochemical basics for energy production and utilization in the cell have been 
established in the last century, defining the main metabolic machinery and 
pathways present in the vast majority of cells. The six-carbon sugar glucose is one 
of the major energy substrates for the cell, providing its energy in form of ATP that 
is formed in the catabolic process of glycolysis. In the glycolytic pathway, glucose 
gets stepwise broken down to two molecules of pyruvate, which is then able to 
either enter the mitochondria, where it acts as a substrate for the TCA cycle and 
subsequent oxidative phosphorylation (oxphos) that yields highly efficient ATP 
production or transformed to lactate and secreted (Figure V). Recently, the 
importance of metabolism in T cell activation and effector function has been 
rediscovered as aberrant energy metabolism can lead to changes in cellular 
behavior and in turn immunological metabolic diseases. As the main research 
interest in the last years has been to delineate the biochemical pathways activated 
during T cell activation, I will mostly focus on this aspect of T cell biology in 
homeostatic settings. 
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Figure V Main intracellular metabolic pathways (Buck et al., 2015) 
The main biochemical pathways that support T cells activation and function include Glycolysis, the TCA 
cycle and subsequent oxidative phosphorylation in the electron transport chain. Furthermore, fatty acid 
oxidation (FAO) and synthesis (FAS), amino acid metabolism and the pentose phosphate pathway (PPP) 
that yields precursors for nucleotide synthesis are critical for T cell activation and function. 
 
 
2.2.2 T cells increase glycolysis, but mitochondrial oxidative 
phosphorylation is sufficient for activation 
 
The specificity of an immune response arises from the presentation of antigen to a 
naïve T cell, which in turn gets activated and starts proliferating at a very high rate, 
reaching duplication times of only 2 hours (Yoon et al., 2010). In order to achieve 
such a substantial proliferation capacity, T cells adapt a highly glycolytic 
metabolism that allows them to provide biosynthetic precursors as well as reducing 
equivalents in the form of Nicotinamide dinucleotide phosphate (NADPH), required 
for macromolecule synthesis. Although the engagement of a glycolytic metabolism 
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in the activation and proliferation of T cells is a well-documented phenomenon 
(MacIver et al., 2013), it has been recently shown that mitochondrial oxidative 
phosphorylation (oxphos) is sufficient for the activation of naïve T cells (Sena et al., 
2013). In the absence of glucose, but presence of pyruvate and glutamine, CD4+ T 
cells are still able to up-regulate the activation markers CD25 and CD69 as well as 
IL-2 mRNA. Pyruvate is an indirect metabolic substrate of oxphos, which is 
concomitant with the production of ROS due to the leaking of the electron transport 
chain. Electron leak occurs when the electrons in the respiratory chain exit before 
the reduction of oxygen to water at the cytochrome c  oxidase and instead react 
with oxygen directly to form the oxygen radical superoxide (Jastroch, 2010). Sena, 
et.al. (2013) showed the critical involvement of mitochondrial ROS production for 
the antigen dependent activation process. T cells deficient in mitochondrial complex 
III failed to induce IL-2 mRNA and nuclear translocation of Nuclear Factor of 
Activated T-cells (NFAT), a determining transcription factor involved in T cell 
activation and function (Macian, 2005; Sena et al., 2013). Yet, although oxphos is 
required and sufficient for T cell activation, over-activation or mitochondrial 
damage causes increased, harmful ROS production that can lead to apoptosis 
(Hildeman et al., 1999). It was thus proposed that proliferating cells adapt a 
glycolytic metabolism in order to reduce oxidative damage and sustain activation 
and proliferation (Brand and Hermfisse, 1997). 
 
 
2.2.3 T cell activation requires PPP activity 
 
Increase of aerobic glycolysis and associated up-regulation of the pentose 
phosphate pathway (PPP) provides a two-way system for the prevention of 
oxidative damage via ROS. The pentose phosphate pathway is the cells’ major 
source of NADPH, which is required for the production of glutathione, the most 
abundant reactive oxygen scavenger and regulator of the cellular redox state. 
Increased intracellular reduced glutathione (GSH) has been associated with 
enhanced survival rate of activated T cells in vitro upon IL-2 withdrawal (Hyde et 
al., 1997). In Jurkat T cells, the glutamine-induced rise in glutathione levels was 
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2.2.4 Amino Acid metabolism supports activation 
 
Glutamine uptake and metabolism has been shown to be crucial for T cell activation 
and proliferation (Carr et al., 2010). Upon activation glutamine transporters are 
expressed at the plasma membrane in a CD28-dependent manner and enzyme 
activities involved in glutamine metabolism in the TCA cycle are enhanced. 
Accordingly, withdrawal of glutamine from the culture medium in the course of T 
cell activation leads to decreased proliferation and cytokine production, which 
cannot be rescued by the supplement of biosynthetic precursors of glutamine (Carr 
et al., 2010). As glutamine is a major building block for fatty acid synthesis in 
oxygen-deplete conditions and a direct substrate for the preservation of the TCA 
cycle, the need of glutamine for T cell activation is not surprising (Fendt et al., 
2013). 
 
Glutamine is not the only amino acid that is required for functional T cell activation. 
The sulfur-containing cysteine – a part of the previously mentioned tri-peptide 
glutathione – is absolutely necessary for T cells to proliferate (Levring et al., 2012). 
The authors of this publication showed that early activation events in the T cell are 
cysteine independent, but as the cells started to proliferate, cysteine transporters 
were up-regulated and cysteine uptake increased. An earlier study showed that 
antigen presenting cells release reduced cysteine into the extracellular space to 
allow for T cell proliferation (Angelini et al., 2002; Edinger and Thompson, 2002). 
The uptake of cysteine possibly enables the T cell to maintain a reduced 
intracellular environment promoting macromolecular synthesis for duplication 
events. 
 
The degradation of tryptophan by macrophages has also been proposed as 
underlying mechanism leading to decreased T cell proliferation, a mechanism 
proposed to be important for the induction of tolerance. Macrophages that 
differentiate in the presence of Macrophage colony stimulating factor (M-CSF) start 
to express indoleamine 2,3-dioxygenase (IDO), which is responsible for intracellular 
tryptophan degradation (Edinger and Thompson, 2002; Munn et al., 1999), thereby 
diminishing extracellular availability of tryptophan. The uptake and metabolism of 
extracellular amino acids seems to be crucial for T cell activation and clonal 
expansion. Sinclair et. al. (2013) showed that a number of amino acid transporters 
were up-regulated during activation and clonal expansion. Large neutral amino acid 
transporter (Slc7a5)-knockout mice were unable to undergo metabolic adaption 
upon antigen stimulation and furthermore failed to induce T cell proliferation or 
effector functions (Sinclair et al., 2013). 
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2.2.5 Post Translational modifications during T cell activation and function 
 
A variety of post-translational modifications (PTMs) for proteins are known, 
amongst which are phosphorylation, acetylation, methylation or parylation. As all of 
them can have immense impact on protein and cellular function, PTMs are tightly 
regulated and able to change rapidly. Chylek et al. (2014), could demonstrate 
global changes in the phosphoproteome that occur seconds after T cell receptor 
activation (Chylek et al. 2014). Similarly, a recent report identified dynamic 
changes in arginine methylation during the activation of primary CD4+ T cells 
(Geoghegan et al., 2015). The authors used a novel method of isomethionine 
methyl-SILAC coupled to arginine methylated peptide enrichment to identify more 
than 2500 methylation sites on arginine residues that drastically change during the 
course of T cell activation. 
 
The attachment of an acetyl- group to a protein moiety (acetylation) however, 
represents the largest group of PTMs investigated to date. From its discovery 51 
years ago, protein acetylation has been recognized as one of major regulators of 
cellular fate and function and is known to be an indicator of the metabolic state of a 
cell (Verdin and Ott 2015). The TCA cycle intermediate Acetyl-CoA forms the basic 
molecule that is attached to a lysine residue via histone acetyl-transferases and 
detached from deacetylases. The latter class of enzymes includes the NAD+ 
dependent sirtuins, which are regulated by a wide variety of metabolic signals and 
play important roles in mitochondrial metabolism, aging and the effects of calorie 
restriction (Canto and Auwerx, 2009). 
 
Another class of NAD+ dependent enzymes involved in the regulation of PTMs is the 
Poly-(ADP Ribose) Polymerases (PARPs), which add long chains of PAR moieties to 
proteins. PARylation plays important roles in a number of cellular processes 
including DNA repair, apoptosis, chromatin modifications or mitosis (Kim et al., 
2005). It was recently proposed that PARylation could contribute to cellular 
architecture, stability and flexibility as it has been shown to be involved in a range 




2.2.6 Fatty Acid Oxidation promotes T cell activation in inflammatory 
conditions 
 
Given the above data, T cell metabolism in activation and proliferation seems to be 
more complex than previously appreciated. Adapting a Warburg-like metabolism 
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might still be an important hallmark, yet following antigen recognition T cells 
simultaneously up-regulate several metabolic pathways, including oxidative 
phosphorylation, amino acid metabolism, TCA cycle and the pentose phosphate 
pathway during acute infections. Chronic inflammatory conditions might further 
complicate this issue. A recent report from Byersdorfer et.al. (2013) showed, that 
alloreactive T cells utilized Fatty Acid Oxidation (FAO) for the activation process in 
graft versus host disease (GVDH). The authors observed an increase in palmitate 
utilization in alloreactive compared to syngeneic T cells, which correlated with 
enhanced IFNγ production. Both mitochondrial acylcarnitine tranporters CPT1a and 
CPT2 as well as PPARγ coactivator PGC1α were up-regulated, all required for 
optimal FAO. This could be observed in multiple models of GVDH. Accordingly, 
blocking FAO by using the selective CPT1a inhibitor etomoxir, resulted in a marked 
inhibition of T cell proliferation (Byersdorfer et al., 2013). Contrarily, Wang et.al. 
(2011) found that activation of T cells within the first 24 hours of antibody 
mediated TCR triggering involved a metabolic adaption that favored the 
accumulation of glycolytic, glutaminolytic and pentose phosphate pathway 
intermediates in addition to higher oxygen consumption. Simultaneously, 
metabolites of the TCA cycle and FAO were markedly decreased. They furthermore 
could show that Glutamine but not Glucose deprivation led to an inhibition in cell 
growth and reduction in the biosynthesis of proteins and lipids. Interestingly, the 
absence of either glucose or glutamine resulted in a marked decrease of cell 
proliferation. Consistent with their previous results, small molecule inhibition of 




According to these data it can be clearly seen that activation and proliferation are 
two distinct features that constitute different metabolic requirements for a T cell. 
These involve the differential utilization of energy substrates that goes along with 
the activity of distinct biochemical pathways. According to the physiological or 
pathological setting, T cells do not seem to merely rely on one specific metabolic 
pathway or energy substrate to meet their ‘metabolic demands’, but rather adapt to 
their microenvironment and available energy sources in order to achieve activation 
or proliferation (Byersdorfer et al., 2013; Edinger and Thompson, 2002; Sinclair et 
al., 2013; Wang et al., 2011). In light of this it is becoming clear that metabolism, 
nutrient availability and factors in the surrounding microenvironment affect the 
function of a T cell on various levels. 
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2.3 THE INFLAMMATORY MICROENVIRONMENT 
 
Once activated T cells reach the inflammatory site, they are subjected to a variety 
of different micro-environmental stimuli likely to impact the ongoing immune 
response. Low glucose and nutrient concentration, oxygen pressure (hypoxia) and 
decreased pH are commonly associated with chronic inflammation (Haas et al., 
2013) (Figure VI). Additionally, elevated levels of ROS, free fatty acid and 
cholesterol concentrations as well as cell debris and metabolic end products are 
often found to be concentrated in sites of an inflammation (Haas et al., 2013). 
 
	  
Figure VI Mediators in the Inflammatory Microenvironment affect T Cell 
Function (Haas et al., 2013) 
Soluble factors in the inflamed microenvironment affect T cells in their functional and behavioural 
patterns. Lactate, low pH, reactive oxygen species, fatty acids of low oxygen concentration exert 






One aspect of inflamed tissues is, that they are often accompanied by low oxygen 
concentrations (<2%) also known as hypoxia (Gaber et al., 2013). Not only is 
oxygen supply in inflammatory sites often reduced due to vascular occlusion and 
thrombosis (Eltzschig and Carmeliet, 2011), but also infiltrating metabolically active 
immune cells, resident epithelia and vascular endothelia show high demand for 
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oxygen (Grenz et al., 2012). This makes it clear that hypoxia and immune cell 
infiltration are connected in a feed forward loop that promotes the establishment of 
chronic disease. 
 
The absence of oxygen has profound effects on the function and fate of a T cell by 
inducing the master transcription factor Hypoxia inducible factor (Hif1α) (Bollinger 
et al., 2014; Pollizzi and Powell, 2014). Under normoxic conditions (2-3% oxygen) 
Hif1-α is hydroxylated by prolyl-hydroxy-domain containing enzymes (PDHs), which 
target it for ubiquitinylation-dependent proteosomal degradation. Hypoxia on the 
other hand inactivates the PDHs and in turn activates the translocation of Hif1α into 
the nucleus and transcription of its more than 200 target genes (Ong and 
Hausenloy, 2012). Targets of Hif1α include genes responsible for energy 
metabolism, cell differentiation, migration and apoptosis (Liu et al., 2012). Upon 
exposure to hypoxia, T cells enhance their activation of survival pathways, yet 
simultaneously decrease their cytokine production, which was proposed to be a 
protective mechanism against tissue destruction (Gaber et al., 2013; Sitkovsky and 
Lukashev, 2005). Surprisingly, CD8+ T cells have been shown to be unaffected or 
even have enhanced cytolytic properties in hypoxic conditions, contrary to their 




2.3.2 Reactive Oxygen Species 
 
The presence of reactive oxygen species (ROS) has historically been associated 
with a decrease in cellular function. Yet some studies show a crucial role for ROS in 
intracellular signaling, apoptosis induction, cell activation and metabolic feedback 
mechanisms (Sena and Chandel, 2012). Interestingly, the authors of this study 
propose a model for ROS-dependent cell activity, whereby the concentration of 
intracellular H2O2 critically determines the cellular response. In homeostatic 
conditions low ROS levels are sufficient to keep the metabolic and cellular activities 
constant. Upon exposure to stress stimuli, ROS levels rise to meet the metabolic 
demands for cell activation and function and are required for proper T cell 
activation (Sena et al., 2013). T cells isolated from Uqcrsf1-/- mice that show 
reduced mitochondrial ROS where unable to induce NFAT-dependent IL-2 induction 
necessary for activation. These cells could not undergo antigen-dependent 
activation in vivo, yet their proliferative potential remained unchanged (Sena et al., 
2013). This study elegantly demonstrated the crucial role for mitochondrial ROS in 
T cell activation. In inflammatory conditions ROS levels are raised due to increased 
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release of H2O2 and superoxide by neutrophils and macrophages (Eltzschig and 
Carmeliet, 2011). Elevated ROS levels exert cell-damaging effects that ultimately 
lead to senescence and cell death due to their highly reactive nature (Sena and 
Chandel, 2012). In addition to that, ROS have been implicated to serve as potent 
intracellular signaling molecules, altering the proteome of activated T cells both in a 
qualitative and quantitative manner and making them important mediators in 





Changes in intra- and extracellular pH can have tremendous effects on cell function 
and viability. A decrease in pH for a few points from the neutral 7.5 potentially 
inhibits most cellular functions, including cAMP and calcium signaling, DNA and 
protein synthesis as well as some enzyme activities (Lardner, 2001). Every enzyme 
has an optimal pH value that is dependent on the amino acid composition and 
linked secondary structure of the protein. The pH value affects the ionization state 
of charged acidic (carboxylic) or basic (amino) functional groups due to 
modification of hydrogen bonds between the amino acid termini. This leads to 
denaturation or alteration in the secondary structure of the enzyme that has direct 
consequences on the confirmation and function of the enzyme. 
 
Interestingly, some studies show extracellular decrease in pH connected to an 
increase in cellular function. Trevani et.al. (1999) showed that a decrease of 
extracellular pH to 6.5 enhanced the activation of neutrophils, thereby intensifying 
the immune response (Trevani et al., 1999). The reduced pH value led to a 
concentration of intracellular calcium levels that promoted the production of 
hydrogen peroxide and subsequently enhanced the capability of microbial lysis 
(Trevani et al., 1999). T cells on the other hand have been found to be negatively 
affected by a pH reduction. Both migratory properties and cytolytic function were 
impaired in a low pH environment, attributed to possible changes in the protein 
conformation states as described above (Lardner, 2001; Redegeld et al., 1991). 
 
In conclusion, the inflammatory microenvironment harbors several physical and 
chemical factors that influence the activity and function of infiltrating immune cells 
and might contribute to the progression and outcome of chronic inflammatory 
diseases. Below, I will describe some characteristics of infiltrating T lymphocytes 
that have been observed in chronic inflammatory conditions. 
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2.3.4 Effector T Cell Characteristics in Chronic Inflammatory Conditions 
(Rheumatoid Arthritis) 
 
Chronic inflammatory diseases, such as rheumatoid arthritis (RA) are a major 
health burden in the United Kingdom, affecting more than 580,000 people in 
England and Wales (NHS, 2014). Joint inflammation caused by elevated pro-
inflammatory cytokine levels and infiltrating immune cells leads to swelling of the 
joints, cartilage and bone destruction that causes insufferable pain to the patients. 
The development of biological agents has brought great advances in the treatment 
of rheumatoid arthritis. These include the monoclonal antibodies infliximab and 
Etanercept against soluble TNFα (Scheinfeld, 2004) and the IL1β inhibitor ACZ885 
(Alten et al., 2008), which inhibit the activity of these two inflammatory cytokines, 
reduce joint inflammation and cartilage destruction. Despite this substantial 
progress some underlying disease mechanisms are still incompletely understood. 
 
RA and other chronic inflammatory disorders are accompanied by infiltrating T cells, 
which represent the predominant cell type in the site of inflammation (Bankhurst et 
al., 1976). Increasing evidence suggests that besides genetic dispositions, the 
prevailing microenvironment contributes to the phenotype of T cells observed in 
inflammatory conditions (Haas et al., 2013). T lymphocytes present in chronic 
inflammatory diseases show specific phenotypes that might contribute to the 
disease development and severity. 
 
Germann et al. (1996) have shown that IFNγ producing Th1 CD4+ T cells are 
present in the rheumatic synovial joint and their number correlates with disease 
severity. Additionally, treatment with IL-12, a T helper type 1 (Th1)-inducing 
cytokine, worsens the disease outcome (Germann et al., 1996). Contrarily, a study 
from (Pene et al., 2008) shows that T cells isolated from the synovial fluid from 
arthritis patients mainly display a phenotype skewed towards Th17 polarization and 
supporting this view, the rheumatoid synovia is enriched in the pro-inflammatory 
cytokines IL-17, IL-22 and TNFα (Al-Saadany, 2015). In contrast to their 
homeostatic function, CD4+ T cells show proliferative hypo responsiveness to TCR 
ligation that might stem from prolonged exposure to high levels of pro-
inflammatory TNFα. Synovial CD4+ T cells have been furthermore described to 
display diminished glycolytic activity, attributed to an insufficient ability to 
upregulate the glycolytic activator Pfkfb3 (Yang et al., 2013). This deficiency was 
accompanied by reduced ATP generation and enhanced autophagic activity (Yang et 
al., 2014), rendering the T cells metabolically inert and prone to apoptosis. 
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Characterization of rheumatoid arthritis patients has also revealed a distinct 
phenotype of CD8+ T cells present in the synovial fluid. These cells were found to 
be mainly activated memory T cells (CD45RA-) with high surface expression of 
CD80, CD86 and PD1 (Cho et al., 2012). The authors furthermore describe a 
marked reduction in the cytolytic activity of the cytotoxic T lymphocytes, yet 
increased expression of IL-4. Intriguingly, several of the glycolytic activator and 
nutrient sensing proteins, including AKT1, AMPK and LKB1 where shown to control 
the switch from cytotoxic to effector memory T cells, which also hints toward a 
glycolytic reduction in synovial CD8+ T cells (Finlay and Cantrell, 2011; Mathis and 
Shoelson, 2011; Spies et al., 2012). 
 
Overall these data describe a distinct T cell phenotype in chronic inflammatory 
conditions, including increased pro-inflammatory cytokine production, reduced 
proliferative and cytotoxic activity as well as generally decreased metabolic activity. 
Partly, these characteristics might stem from genetic conditions and factors that are 
independent from the site of inflammation and affect the T lymphocytes 
systemically. TCR rearrangement excision circles (TREC), products of the TCR 
rearrangement, can be detected in T cells that recently emigrated from the thymus 
in to the periphery and is a measure for newly generated T cells from the thymus 
(Koetz et al., 2000). Blood analysis from RA patients showed decreased TREC 
values compared with healthy controls, pointing towards a systemic altered T cell 
dynamic in RA (Koetz et al., 2000). In agreement with the above argument, the 
majority of peripheral blood T cells in RA were found to be CD4+CD28- (Pawlik et 
al., 2003), a phenotype that was recently shown to produce higher levels of TNFα 
and IFNγ after TCR crosslinking (Pieper et al., 2014). Interestingly, the same study 
described T cells showing coproduction of IL-17 only when present in the rheumatic 
synovia. This finding again suggests that factors in the inflammatory 
microenvironment may affect the normal function of the cells, which in turn 
contribute to the disease outcome (Pieper et al., 2014). 
 
Below, I will describe some signaling aspects of lactate, another factor that is 
commonly found enriched in inflammatory conditions. 
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2.4 LACTATE AS SIGNALLING MOLECULE 
 
Lactate is a ubiquitous molecule, whose presence in the mammalian body has first 
been observed in muscle tissue at the beginning of the 19th century (Kompanje et 
al., 2007). Since its discovery, lactate has been intensely studied and numerous 
functions in regulating metabolic homeostasis have been defined, which includes 
the well-known Cori cycle, a metabolic cross talk between the liver and the muscle. 
Here, muscle tissue metabolizes liver derived glucose to lactate, which in turn is 
shuttled back to the liver and acts as a fuel source for hepatic gluconeogenesis 
(Cornell et al., 1973). In the brain on the other hand, lactate acts as a metabolic 
signal and fuel for oxidative metabolism, which builds the basis of the astrocyte - 
neuron lactate shuttle hypothesis (ANLS) (Pellerin and Magistretti, 1994). 
 
 
2.4.1 The Astrocyte - Neuron Lactate shuttle hypothesis 
	  
In the brain, lactate has first been postulated to serve as a metabolic fuel secreted 
from astrocytes and taken up by neurons to enforce oxidative metabolism – a 
hypothesis known as the astrocyte-neuron lactate shuttle (Magistretti et al., 1994). 
Early indications came from parallel measurements of blood flow changes, glucose 
usage and oxygen consumption measured by Positron Emission Tomography (PET) 
((Fox and Raichle, 1986; Pellerin and Magistretti, 2003). The authors observed an 
uncoupling of oxygen consumption from glucose utilization that resulted in a 
transient elevation of extracellular lactate levels. Interestingly, it was coincidentally 
reported that astrocytes, a type of glial cells, stimulate glucose uptake and lactate 
secretion in the presence of the neurotransmitter glutamate (Pellerin and 
Magistretti, 1994), which was further supported by the observation that glial cells 
constitute the majority of glucose-consuming cells in the brain (Pellerin and 
Magistretti, 2003). However, this glutamate dependent glycolytic increase has been 
challenged in later reports that show how culture conditions, specifically oxygen 
and glucose concentration in the culture medium dictates the preferred metabolic 
pathway utilization in astrocytes (Hertz, 2004). 
Regardless of whether astrocytes increase their glucose consumption and lactate 
secretion due to glutamate uptake or not, the generally proposed ANLS hypothesis 
is explained as follows: During neuronal activation, glutamate is released into the 
synaptic cleft where it acts as a neurotransmitter. Astrocytes take up the 
glutamate, which causes an increase in glycolysis with concomitant production and 
release of lactate. Shuttling lactate back into the extracellular space via short 
monocarboxylate transporters (Mct) increases lactate availability to neurons and 
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enables them to use it as fuel for oxidative metabolism ((Magistretti et al., 1994; 
Tarczyluk et al., 2013). Although there still exist discrepancies of results and 
inconsistencies in the exact mechanism of the ANLS, the role of lactate as an intra- 
and extracellular signal still remains. 
2.4.2 Lactate Transport 
 
Lactate transport through the plasma membrane is mediated by six so far described 
short monocarboxylate transporters (Slcs), which are either proton (Mct 1-4) or 
sodium (Slc5a8, Slc5a12) dependent (Halestrap, 2012; Srinivas et al., 2005). 
Slc5a8 and Slc5a12 are mainly expressed in kidney and intestine respectively, 
where they are thought to act mostly as means of lactate reabsorption and dietary 
short monocarboxylate uptake (Srinivas et al., 2005). 
 
Based on the structural similarity of conserved sequence motifs, the Mct family 
consists of fourteen members; yet they differ in their substrate specificity, 
transport kinetics and tissue expression (Halestrap, 2012). Although all 
transporters of the Mct family are able to transport structurally related short 
molecules, Mct1 and Mct4 have the highest specificity for lactate transport and 
show broad tissue expression. Loss of Mct1 has detrimental effects on survival and 
metabolic homeostasis, as Mct1-/- mice are embryonically lethal and heterozygous 
Mct1+/- - although developing normal – are resistant to diet induced obesity, 
underscoring the importance of lactate signaling (Lengacher 2013). Interestingly, 
Mct1 has not only been shown to locate to the plasma membrane, but also to the 
mitochondrial outer membrane, where it might facilitate lactate uptake. This 
supports the hypothesis of that lactate can act as a substrate for oxidation in the 
mitochondria ((Magistretti et al., 1994; Tarczyluk et al., 2013). 
	  
2.4.3 Intracellular lactate signaling pathways 
 
Further evidence that establishes lactate as a signaling molecule comes from the 
identification of the lactate receptor Gpr81, first cloned in 2001 (Lee et al., 2001). 
Seven years later, lactate was identified as the primary ligand for Gpr81, being 
involved in lactate-mediated reduction of lipolysis in adipocytes, the primary Gpr81 
expressing cell type (Cai et al., 2008). It is now clear that Gpr81 is a G-protein 
coupled receptor inhibiting the adenylyl cyclase via the Gi signaling pathway (Ge et 
al., 2008) and mediates the insulin-induced reduction of lipolysis (Ahmed et al., 
2010; Liu et al., 2009). Interestingly, several reports identify the lactate receptor 
as critical survival signal for cancer cells (Roland et al., 2014; Staubert et al., 
39 / 123 
	  
2015), and define it as a therapeutic target in ischemic brain injury (Shen et al., 
2015). 
 
Lactate has two primary means of relaying signals into the cell, receptor- and 
transporter mediated, with the Mct family representing the most abundant lactate 
transporters (Halestrap and Price, 1999). Once in the cytoplasm, lactate is readily 
oxidized to pyruvate by the LDH. This reaction proceeds with a concomitant proton 
transfer from lactate to NAD+ thereby generating NADH and affecting the redox 
state of the cell. Although LDH is mainly considered a cytoplasmic enzyme, after 
years of controversy, the existence of a mitochondrial LDH has finally been proven 
(Brooks et al., 1999) and in combination with the presence of Mct1 in the 
mitochondrial membrane (Hashimoto et al., 2006), lactate metabolism is now being 
considered as an active part of mitochondrial metabolism. Very recently, also the 
localization of the LDH subunit B (LDHB) to the peroxisomes has been shown in 
fibroblasts and HeLa cells (Schueren et al., 2014). However, the significance of this 
finding has not yet been fully elucidated. 
 
Besides the changes in redox signaling, lactate has been shown to affect cellular 
metabolism in several ways. A report from Leite et al. (2011), shows that lactate 
inhibits the enzymatic activity of purified phosphofructokinase (Pfk) from murine 
skeletal muscle, liver and kidney tissues. This effect was mediated by the inhibition 
of tyrosine phosphorylation on Pfk, and important signal for kinase activation. The 
authors proposed that lactate might play a role in the inhibition of glycolytic 
metabolism, hereby serving as an inhibitory feedback mechanism.  
 
A recent report sheds light on another aspect of intracellular lactate signaling as it 
describes the direct binding of lactate to N-myc downstream-regulated gene 3 
(NDRG3) during hypoxia, which is in turn stabilized and executes an ERK1/2-
mediated pro-angiogenic program (Lee et al., 2015). This effect is completely 
independent of Hif1α involvement, which is surprising, as lactate is also known to 
induce a state of ‘quasi-hypoxia’ and the activation of Hif1α in various tissues 
(Colegio et al., 2014a, b; Sonveaux et al., 2012). 
 
Additionally, lactate has very recently been shown to induce the reactive oxygen 
species superoxide and H2O2 in isolated rat hearts (Gabriel-Costa et al., 2015). This 
study further reports the increase of NADH oxidase and superoxide dismutase 2 
activities, which are both indicators of an antioxidant response, as NADH is the 
main substrate for mitochondrial ROS production. In line with these findings, also 
Nrf2 and Pgc1α levels were increased, both transcription factors that regulate 
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mitochondrial biogenesis and improve mitochondrial function (Dinkova-Kostova and 
Abramov, 2015; Scarpulla et al., 2012). 
 
Thus, it appears that the effects of lactate vary with the type of tissue investigated. 
So far, only a few reports have addressed the influence of extracellular lactate on 
the function of immune cells, which I will discuss in the next section. 
 
  
2.4.4 The effect of lactate on immune cells 
 
Recent reports suggest that lactate acts as an active metabolic signaling molecule 
in a number of pathologies, which has immense implications for chronic diseases. 
Studies from (Su et al., 2014) and (Colegio et al., 2014a) show a lactate-mediated 
effect on macrophages in the tumor microenvironment. Similar to chronic 
inflammatory conditions, the tumor microenvironment contains high concentrations 
of lactate, which can reach up to 30mM (Hirschhaeuser et al., 2011). Here, lactate 
produced by tumor cells is taken up by macrophages where it promotes polarization 
towards an anti-inflammatory, Arginase 2 (Arg2) expressing M2-like phenotype, via 
stabilization of Hif1α and increased Vascular Endothelium Growth Factor (VEGF) 
production. These effects further enhance tumour growth in a malicious loop 
(Colegio et al., 2014b). Strikingly, Colegio et al. (2014), applied an unbiased high-
throughput screen to look for unknown proteins perpetuating this loop, but 
identified lactate as the orchestrating factor. Similarly, Su and colleagues recently 
found lactate being the driving force behind tumor associated macrophage (TAM) 
development during epithelial to mesenchymal transition (Su et al., 2014). 
 
These findings are in line with previous reports that show how targeting the lactate 
transporter Mct1 in endothelial cells or cervix squamous carcinoma cells rescues 
lactate-induced Hif1α activation and inhibits the consequential angiogenesis 
(Sonveaux et al., 2012; Sonveaux et al., 2008). In a follow up study, the authors 
of these studies could demonstrate that the induction of angiogenesis is mediated 
via the IkB/NF-κB pathway that drives IL8 expression and leads to increased 
endothelial migration thereby promoting tumor metastasis (Vegran et al., 2011).  
 
Interestingly, it has been long known that inflammatory sites harbor high 
concentrations of lactate and that this increase in lactate concentrations stems from 
a deregulation of cellular metabolism. Although lactate has mainly been considered 
as a metabolic waste byproduct of glycolytic metabolism, it is now becoming 
increasingly clear that augmented concentration of lactate can have detrimental 
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effects in many diseases, most prominently cancer, as it was impressively 
demonstrated by Su et al. (2014), Colegio et al. (2014) and the group led by Pierre 
Sonveaux (De Saedeleer et al., 2014; Perez-Escuredo et al., 2015; Van Hee et al., 
2015). Despite these observations, the effect of elevated lactate on T cells in 
chronic inflammatory diseases has not been investigated to date. 
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3 RATIONALE AND AIM 
 
Acidity is a feature of inflammatory sites such as arthritic synovia, atherosclerotic 
plaques, and tumor microenvironments and results in part from the accumulation of 
lactate as a product of glycolysis under hypoxic conditions. It has recently emerged 
that lactate may be more than just a bystander product of certain metabolic 
activities / pathways but rather may actively participate to the ongoing immune-
inflammatory response. 
 
In light of this, the aim of this project was to elucidate the relative contribution of 
elevated lactate concentrations on T cell migration and function in the context of 
chronic inflammation. I hypothesized that lactate in inflammatory sites exerts a 
feedback mechanism to infiltrating T cells, thereby potentially contributing to some 
of the T cell characteristics reported in chronic inflammation and subsequently to 
the establishment and progression of chronic inflammatory diseases (CIDs). 
 
As lactate is a product of glycolysis I was to investigate the metabolic basis of T cell 
migration and function and to delineate specific biochemical pathways, in particular 
glycolysis, that define the necessary prerequisites and make it possible for T cells to 
migrate and function. 
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4 MATERIALS AND METHODS 
 
4.1 Chemicals and reagents 
 
All chemicals and reagents were purchased from Sigma-Adlrich & Co (UK), unless 
otherwise specified. A list of antibodies and buffers used can be found in section 8 
(Appendix, table 3 and 4). 
 
4.2 T cell isolation, in vitro activation and subset enrichment 
 
Lymph nodes isolated from superficial cervical, deep cervical, axillary, brachial, 
mesenteric, inguinal or lumbar regions, or spleen of C57BL/6 mice (JAX) were 
smashed through a 45um pore cell strainer to obtain the lymphocytes. The cells 
were washed and subsequently activated for 3 to 5 days with plate bound 1µg/ml 
anti-CD3 (clone 17A2, Biolegend) and 5µg/ml anti-CD28 antibodies (clone 37.51, 
Biolegend), and 10ng/ml IL-2 (PeproTech) in RPMI 1640, supplemented with 10% 
fetal bovine serum (FBS). CD4+ and CD8+ T cell subsets were isolated with 
commercially available negative selection magnetic bead isolation kits (Easysep, 
Invitrogen) according to manufacturer’s instructions and experimental settings 
either prior or post activation. Successful activation of cells was confirmed via light 
microscopic observation of cell morphology and size. 12h before the assay, the 
media was changed to RPMI 1640 with 2% FBS. 
 
Human blood was obtained from healthy donors according to ethics approval from 
Queen Mary Ethics Research Committee (QMERC2014/61). Briefly, Peripheral Blood 
Mononuclear Cells (PBMCs) were isolated using a single density centrifugation 
(Histopaque 1077). CD4+ or CD8+ T cells were then isolated from the PBMCs using 
negative isolation Dynabeads® magnetic separation (Invitrogen), according to 
manufacturer’s instructions. Untouched human CD4+ and CD8+ T cells were 
stimulated for 5 days with 0.5µg/ml of soluble anti-CD3 (clone Hit3a) and 0.5µg/ml 
of anti-CD28 (clone CD28.2, Biolegend), together with 10ng/ml IL-2 (Peprotech). 
 
4.3 Chemokinesis assays 
 
Chemokinesis assays were performed in 3 and 5µm transwell inlays (Corning) for 
naïve and activated T cells respectively. In some experiments, T cells were pre-
treated overnight with a number of drugs: 200nM Rapamycin (Calbiochem), 1mM 
2-DG, 2mM Metformin (Calbiochem). In most experiments cells were incubated 
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with 10mM lactic-acid or 10mM sodium lactate 1 hour before the assay and 
migrated in the presence of lactate, either alone or in combination with 25 µM 
Phloretin, 425µM α-cyano-4-hydroxycinnamate (CHC), 8 - 92nM AR-C155858 
(Tocris Bioscience), 2.5µg/ml Slc5a12 specific antibody (ab107749 Abcam) or 
2.5μg/ml Slc16a1 specific antibody (ab90582 Abcam), 25µM PJ-34 or 1µM Ex-527 
(Gertz et al., 2013). Briefly, 3x105 lymphocytes were seeded in the upper transwell 
chamber whereas chemokines (PeproTech) were added to the lower chamber: 
300ng/ml CXCL10, 50ng/ml CCL5 or 100ng/ml CCL19/21 of each chemokine. 
Migrated T cells were counted with a hemocytometer 2, 4 and 6 hours after seeding 
and percent of migrated cells was calculated. 
 
4.4 Determination of Cell Death 
 
T cell viability upon lactate or metabolic drug treatment was assessed by trypan 
blue exclusion assay. Whenever necessary, dead cells were removed using Ficoll-
Paque Plus (GE Healthcare). 
 
4.5 RNA isolation and reverse transcription 
 
Total RNA was isolated from 106 T cells or 10mg RA synovial tissue using RNeasy 
Mini kit (Qiagen) or Trizol (Life Technologies) according to the manufacturer’s 
instructions and assessed for quality and quantity using absorption ratios of 
260/280nm and 260/230nm. Hereby cells were lysed in lysis buffer RLT, nucleic 
acids were precipitated with 70% ethanol and RNA bound to spin columns. 
Following several washing steps, RNA was eluted in dH2O. The isolated RNA was 
reverse transcribed to complementary DNA (cDNA) using commercially available 
kits according to the manufacturer’s instruction (Applied Biosystems). Briefly, 1ug 
of total RNA was mixed with buffer, deoxy-nucleotides (dNTPs) and reverse 
transcriptase and incubated for 2h at 30°C, followed by a 5min heat inactivation 





Quantitative gene expression analysis was performed using SYBR Green Supermix 
(Biorad) in CFX connect light cycler (Biorad), according to the manufacturer’s 
instructions. Gene relative expression was calculated using the ΔΔct method (Livak 
and Schmittgen, 2001) and normalized to  60S acidic ribosomal protein p0 (Rplp0). 
45 / 123 
	  
Primers for qRT-PCR were designed with the assistance of online tools (Primer 
3Plus) using at least one exon junction binding-site per primer pair where possible. 
A complete list of primers used is available in the supporting information (Table 
S2). Size and specificity of pcr products were confirmed by gel electrophoresis. 
 
4.7 Cell organelle enrichment 
 
Cell compartments were enriched using a Cell Fractionation kit (Abcam) according 
to the manufacturer’s instructions. Here, 6x106 CD4+ T cells were subjected to a 
series of lysis and centrifugation steps to yield cytosolic, mitochondrial and nuclear 
fractions. 
 
4.8 Western blot 
 
Total cell lysates were prepared from activated T cells in cell lysis buffer (50 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) or RIPA buffer (50 
mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL CA-630, 1% sodium 
deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitors (1 mM 
PMSF plus Complete Mini and PhosSTOP; Roche). Cell lysates were cleared from 
insoluble material by centrifugation at 14000xg for 10min at 4°C. Protein lysates 
were boiled at 95°C for 10min in 1x Laemmli buffer (0.1% 2-Mercaptoethanol, 
0.0005% Bromophenol blue, 10% Glycerol, 2% SDS, 63 mM Tris-HCl, (pH 6.8)), 
separated on 4-12% SDS-PAGE and transferred to a Nylon membrane (GE 
Healthcare) for 2h at 200mA. Membranes were blocked for 2h at room temperature 
in 5% non-fat dry milk in 0.1% Tween containing Tris buffered saline (TBST) and 
incubated overnight at 4°C with primary antibodies 1:1000 dilution in 5% non-fat 
dry milk in TBST. Antibody-antigen complexes were visualized with horseradish 
peroxidase-conjugated secondary antibody (Amersham Bioscience) (1:5000) 
against rabbit or mouse and Clarity Western ECL substrate (Biorad). Antibodies 
against hexokinase 1, pyruvate kinase M1/2, Aldolase A, Enolase 1, Pyruvate 
Dehydrogenase, Acetyl-Lysine, phospho AMP-Kinase α (Thr172), total AMP-Kinase, 
phospho acetyl-CoA Carboxylase, total acetyl-CoA Carboxylase, Poly (ADP Ribose) 
Polymerase 1, Histone H3 and β-actin were purchased from Cell Signaling; 
antibodies against Slc16a1 and Slc5a12 were purchased from Abcam; Poly (ADP 
Ribose) (PAR) antibody was purchased from Adipogen (clone 10H). Density of 
bands of glycolytic enzymes was calculated relative to β-actin via the use of Image 
J software. 
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4.9 Enzyme Linked Immunosorbent Assay 
 
Secreted IL-17A was measured in cell culture supernatants from 1x106 CD4+ T 
cells/ml with a Mouse IL-17A (homodimer) ELISA Ready-SET-Go Assay 
(ebioscience) according to the instructions. 
	  
4.10 Lentivirus preparation and cell transfection 
 
Bacterial glycerol stocks containing sh-RNA plasmid clones targeting Slc5a12 or 
unspecific RNAs were purchased from Sigma and grown in Luria Bertani broth. 
Plasmids were isolated using Plasmid Maxi kit (Qiagen). HEK293T cells were grown 
in 10x10cm cell culture dishes to 70% confluence and transfected with plasmids 
using the calcium phosphate method. Hereby bis-buffered saline (BBS) and Calcium 
Chloride (CaCl2) was added drop wise to the diluted plasmid DNA under swirling 
conditions to form calcium phosphate DNA complexes, which was added to the 
cells. The supernatant was harvested 48 and 72 hours after transfection, filtered 
and hundred-fold concentrated in an ultracentrifuge at 20000xg for 2h. Aliquots 
were stored at -80°C. 
 
4.11 Lentiviral transduction and sh-RNA-mediated gene silencing 
 
Primary CD4+ T cells were isolated and activated as described above. On day 3 of 
activation, medium was refreshed and cells were incubated with 25µl virus/106 cells 
/ml in the presence of 8µg/ml Hexadimethrine bromide (polybrene, Sigma). The 
virus was removed 24h later and the T cells were washed twice with PBS and 
incubated for 24h in complete RPMI culture media. Knockdown efficiency was 
confirmed by qRT-PCR and Western blot. 
 
4.12 Measurement of extra- and intracellular metabolites and ROS 
	  
Lactate concentration was measured in the synovial fluid or peritoneal lavage using 
the colorimetric lactate assay kit (Biovision) according to the manufacturer’s 
instructions. Intracellular metabolites (NAD+/NADH, acetyl-CoA, Citrate, Coenzyme 
A) were measured with colorimetric or fluorescent kits (Biovision) according to the 
instructions. ATP was measured using a Bioluminescence Assay Kit (Sigma). 
 
Samples were collected after 1x wash in complete RPMI culture media and 
quenched in liquid nitrogen to stop metabolism. For acetyl-CoA, Citrate, Coenzyme 
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A and ATP measurements samples were lysed with RIPA buffer and deproteinized 
with Perchloric acid (PCA) and Sodium hydroxide prior to the assay. 
 
Reactive oxygen species were measured using the fluorescent probe carboxy-
H2DCFDA (Invitrogen, Molecular Probes). Briefly, CD4+ T cells were incubated with 
1µM H2DCFDA/PBS for 30 minutes in the dark. The excess dye was removed with 
3x washes in warm PBS and 2.5x105 cells /100µl PBS were plated in a black 96 well 
plate. After addition of 10mM Sodium Lactate or 1mM H2O2 fluorescence was 
recorded in a time wise manner at Ex 492nm / Em 520nm. 
 
4.13  Glucose uptake, flux, oxidative phosphorylation and fatty acid 
oxidation 
 
Basal and active glucose metabolism was measured with a Seahorse XF24 or XF96e 
Extracellular Flux Analyser. Briefly, T cells were grown in high glucose RPMI-1640 
supplemented with 10% FCS. One hour before the experiment, 1x106 or 2.5x105 T 
cells were seeded in a 24 or 96 well micro plate in XF Assay Modified DMEM 
respectively, in the absence (basal) or presence (active) of 10mM Glucose. CXCL10, 
sodium lactate, metabolic drugs or PBS were injected during measurement. 
 
Glucose uptake/flux was measured in T cells pre-treated with 1mM 2-DG, 10mM 
sodium lactate or 10mM lactic acid and then incubated with the fluorescent probes 
2-NBDG or 6-NBDG (Life Technologies). Fluorescence was detected at Ex 465nm / 
Em 540nm. 
 
Rate of basal oxidative phosphorylation was determined by measuring the oxygen 
consumption rate (OCR) in the presence of glucose. Metabolic stress test analysis 
was performed by injecting 10mM glucose, 1µM Oligomycin, 1µM FCCP, followed by 
a combination of 1µM Antimycin A, 1µM Rotenone and 50mM 2-DG. Both assay 
types were performed using a Seahorse XF24 or XF96e Extracellular Flux Analyser. 
 
Fatty acid oxidation was analysed by measuring the OCR with a Seahorse XF96e 
Extracellular Flux Analyser according to the manufacturers protocol. Briefly, 2.5x105 
T cells were seeded in a 96 well micro plate in XF Assay Modified DMEM containing 
2.5mM Glucose and incubated for 45 minutes in a CO2 free incubator. 15 minutes 
prior to the assay, control cells were treated with 40µM Etomoxir to block CPT1a. 
Just before starting the assay, the cells were treated with 167µM BSA-Palmitate or 
BSA alone. During the assay 1µM Oligomycin and 1µM FCCP were injected. 
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4.14 Cytotoxic T Lymphocyte differentiation and activity assay 
 
The CD8+ T cell subset were isolated from balb/c mice and incubated with CD3+ 
depleted and mytomycin C eradicated allogeneic splenocytes from C57BL/6 mice 
for 5 days. Differentiated Cytotoxic T lymphocytes (CTLs) were enriched with Ficoll-
Paque Plus (GE Healthcare) and CD3 enrichment kits and co-cultured with 
endothelial cells (C57BL/6) in the presence or absence of 10mM lactic acid or 
sodium lactate. Dead cells were counted using trypan blue exclusion assay 2, 4, 6 
and 18 hours after the start of the assay. 
 
4.15 T helper subset differentiation 
 
T cells were isolated from murine lymph nodes and enriched for CD3+ and 
subsequently CD4+ subsets. 106 cells were plated per well and differentiated 
towards Th0, Th1, Th2 and Th17 phenotype for 3 days with plate bound 1µg/ml 
anti-CD3 and 5µg/ml anti-CD28 antibodies (BioLegend). Conditions were: Th0 
(10ng/ml IL-2); Th1 (10ng/ml IL-2; 3.4ng/ml IL-12; 2µg/ml Anti-IL4); Th2 
(10ng/ml IL-2; 10ng/ml IL-4; 2µg/ml Anti-IFNγ); Th17 (10ng/ml IL-6; 2µg/ml 
Anti-IL-4; 2µg/ml Anti-IFNγ, 5ng/ml TGFβ). All antibodies and cytokines were 
purchased from PeproTech. Differentiation was confirmed via qRT-PCR, assessing 
expression of IFNγ for Th1, IL-4, IL-5, IL-13 for Th2 and IL-17 for Th17 cells. 
 
4.16 Intracellular cytokine & transcription factor staining 
 
Murine T cells were incubated in permeabilization/fixation buffer (ebioscience) 
overnight at 4°C. Samples were washed in permeabilization buffer (ebioscience) 
and stained for the cytokines IFNγ and IL-17A, using fluorescently conjugated 
primary antibodies (1:200, ebiosciences) at 4°C for 30 minutes. Human isolated 
CD4+ T cells were treated as described above. In the final 6h of culture, cells were 
treated with 50ng/ml phorbol 12-myristate 13-acetate (PMA) and 500ng/ml 
ionmycin and 3µg/ml Brefeldin A (Sigma-Aldrich), followed by surface staining for 
CD4 (clone RPA-T4, Biolegend).  Cells were fixed and permeabilized as described 
above, followed by staining for IL-17A (clone BL168, Biolegend) for 30 minutes at 
room temperature. All intracellular staining was assessed by flow cytometry using a 
LSR Fortessa (BD Biosciences) and FlowJo version 7.6.5 software. 
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4.17 Intracellular Immunofluorescence staining and microscopy 
 
Murine CD4 T+ cells were incubated for 5 minutes with 300nM MitoTracker Deep 
Red FM (Molecular Probes) at 37°C. Cells were washed in PBS and 
fixed/permeabilized in permeabilization/fixation buffer (ebioscience) overnight at 
4°C. Samples were washed in permeabilization buffer (ebioscience) and incubated 
with primary antibodies against Hexokinase 1 (1:200, Cell Signaling Technology) 
for 1h at room temperature. The samples were then incubated with fluorescent 
secondary antibodies (1:200) for 1h at room temperature and 4',6-diamidino-2-
phenylindole (DAPI) for 5 minutes before they were spun down for 5minutes to a 
cover slip in a cytospin centrifuge. Cells were mounted in Mowiol and pictures taken 
on a confocal laser scanning microscope LSM510 (Zeiss). 
 
4.18 Human RA synovial tissue collection and immunohistology/ 
immunofluorescence 
 
RA synovial tissue was collected after informed consent (LREC 07/Q0605/29) from 
a total of 16 RA patients undergoing total joint replacement or ultrasound-guided 
synovial biopsies as previously described (Humby et al., 2009). A summary of the 
demographical and clinical characteristics of the RA patients is reported in Table I. 
For total T cell scoring, paraffin sections were stained for CD3 and a semi-
quantitative score was applied as previously described (Croia et al., 2013). For 
Slc5a12 single and double immunofluorescence with CD4 or CD8, after antigen 
retrieval (S2367, Dako) and block of non-specific binding, slides were incubated 
with primary antibodies either overnight at 4°C (CD4 and CD8, 1:50, Dako) or 1 
hour at room temperature (Slc5a12, 1:50, Novus Biologicals) followed by 
fluorochrome-conjugated secondary antibodies (Invitrogen, Eugene, Oregon, USA). 
All sections were visualised using a Zeiss fluorescence microscope. Quantification 
was performed by calculating the percent of double positive CD4+ Slc5a12+ 
population within the CD4+ or Slc5a12+ cells, or the percent of double positive 
CD8+ Slc5a12+ population within the CD8+ or Slc5a12+ cells. The number of 
positive cells, constituting single and double positive for each marker, was counted 
in 6 images per condition. 
 
4.19 In vivo peritoneal recruitment model 
 
All the in vivo experiments were conducted under the UK Home Office regulation 
(PPL 70/7443). Activated T cells (5x106/mouse) were pre-treated overnight with 
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200nM Rapamycin, 1mM 2-DG or 2mM Metformin, then labelled with the 
fluorescent cell dye 7-Hydroxy-9H-(1,3-Dichloro-9,9-Dimethylacridin-2-One (DDAO, 
Invitrogen) and injected intravenously into syngeneic female C57BL/6 mice that 
had 3 hours prior received an intra-peritoneal injection of 120ng CXCL10 per 
mouse. 24 hours after injection, mice were sacrificed and spleen and peritoneal 
lavage were harvested. T cells were stained for surface markers CD4 and CD8 
(ebiosciences) and analysed by flow cytometry. Cells were first gated on CD4 and 
subsequently analysed for DDAO positivity. 
 
4.20 In vivo zymosan-induced peritonitis 
 
C57BL/6 mice were injected with 1mg zymosan per mouse in the peritoneal cavity 
or left untreated. On day 5, 50µM Phloretin, 5µg/ml anti-Slc5a12 antibody or 
5µg/ml anti-rabbit IgG isotype control antibody (Invitrogen) were injected into the 
peritoneal cavity. 24 hours later, mice were sacrificed and the peritoneal lavage 
was harvested. T cells were stained for surface markers (CD4 and CD8; 
ebiosciences) and analyzed by Flow Cytometry. Alternatively C57BL/6 mice were 
injected in the peritoneal cavity with zymosan (1mg per mouse) on day 0. On day 
5, activated 5x106/mouse CD4+ T cells labelled with 3.3µM of the fluorescent cell 
dye Carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) were co-injected with 
5µg/ml anti-Slc5a12 antibody, 50µM Phloretin or 5µg/ml of an IgG isotype control 
antibody in the peritoneal cavity. 24 hours later, mice were sacrificed and the 
peritoneal lavage and the spleen were harvested. T cells were stained for surface 
markers (CD4 and CD8; ebiosciences) and analyzed by Flow Cytometry. Cells were 
first gated on CD4 and subsequently analysed for CFSE positivity. 
 
4.21 Flow Cytometry 
 
Isolated T cells were stained for surface markers; CD3, CD4, CD8, CD25, CXCR3, 
CCR7, CD62L and LFA-1 with fluorescently conjugated primary antibodies (1:200, 
ebiosciences) at 4oC for 30 minutes, and assessed by flow cytometry using a LSR 
Fortessa (BD Biosciences) and FlowJo version 7.6.5 software.  
 
4.22 Statistical analysis 
 
Data are expressed as mean ± s.e.m. Two-tailed Student’s t-test was used to 
compare 2 groups with parametric data distribution. For multiple comparison 
analysis, 1-, 2- or 3-way ANOVA was used. In all case, a p-value of less than 5% 
was considered to be significant. 




5.1 CHAPTER I – EXTRACELLULAR LACTATE ALTERS MIGRATORY AND 
FUNCTIONAL PROPERTIES OF T CELLS 
 
5.1.1 Lactate inhibits chemokinesis of activated T cells 
 
To assess whether T cell motility is affected by lactate, I performed chemokinesis 
assays of activated T cell subsets in the presence of 10mM lactic acid or sodium 
lactate. CD4+ and CD8+ T cells were separately isolated using negative selection 
beads, activated with anti-CD3 and anti-CD28 antibodies and IL-2 for 5 days and 
the chemotactic response was induced by the pro-inflammatory chemokine 
CXCL10. The lactate concentrations I used could be measured in the synovial fluid 
of osteoarthritis (OA) and RA patients (Figure 1A) and have been found in a 
number of inflammatory sites (Gobelet and Gerster, 1984; Young et al., 2013). I 
found that CD4+ T cell chemokinesis was inhibited by sodium lactate whereas that 
of CD8+ T cells was inhibited by lactic acid but not vice versa (Figures 1B, C). 
 
Chemokinesis can be activated by several structurally unrelated chemokines, 
leading to different responses (Mueller et al., 2007). I therefore also tested the 
chemokinetic effect of lactate on another inflammatory chemokine CCL5. CCL5-
induced motility of CD4+ T cells was again decreased in sodium lactate- but not 
lactic-acid-rich environment (Figure 1F), suggesting a broader action of lactate in 
chemokine-induced signaling and downstream effects than previously anticipated. 
Motility of CD4+ T cells upon sodium lactate treatment decreased with increasing 
concentration of sodium lactate with an EC50 of about 10mM sodium lactate (Figure 
1D). These concentrations of sodium lactate and lactic acid did not affect cellular 
viability (Figure 1G). 
 
As acidification ‘per se’ could affect cellular motility (Lardner, 2001), I performed 
additional chemokinesis assays to discriminate the effects of lactic acid on the 
motility of CD8+ T cells from the effects of pH reduction in the culture media due to 
the addition of 10mM lactic acid. Lactic acid is present in solution either as the acid 
in its associated form at low pH or as the ion salt (i.e. sodium lactate) at higher / 
neutral pH. I found that progressive acidification of medium containing 10mM 
sodium lactate reduced the motility of CD8+ T cells (Figure 1E). The stepwise 
acidification of sodium lactate containing media increases the availability of lactic 
acid. Importantly, neither the presence of sodium lactate in the culture media alone 
nor the sole acidification of the media to pH 4.5 with HCl had any effects on the 
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motility of CD8+ T cells (Figure 1E). These data suggest that inhibition of CD8+ T 
cell motility by lactic acid cannot be simply ascribed to its effect on the pH 
reduction in the culture media. Rather the simultaneous availability of lactate and 
protons (H+) is necessary to regulate the motility of CD8+ T cells. This effect did not 
apply to CD4+ T cells since their migration was not affected in lactic acid-enriched 
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Figure  1 Lactate inhibits effector T cell migration 
(A) Lactate measurements in the synovial fluid of osteoarthritis (OA) or rheumatoid arthritis (RA) 
patients. (B-C) In vitro chemokinesis of activated CD4+ (B) and CD8+ (C) T cells towards CXCL10 
(300ng/ml) in the presence of lactic acid (10mM) or sodium lactate (10mM) shown as kinetic (left panel) 
and 4h time point (right panel). (D) In vitro chemokinesis of activated CD4+ T cells towards CXCL10 
(300ng/ml) in the presence of increasing concentration of sodium lactate shown as kinetic (left panel) 
and 4h time point (right panel). (E) In vitro chemokinesis (4 hour time-point) of activated CD8+ T cells 
towards CXCL10 (300ng/ml) in the presence of sodium lactate (10mM) or HCl (pH 4.5) alone, or sodium 
lactate in combination with increasing concentrations of HCl to obtain progressively reduced pH as 
indicated. (F) In vitro chemokinesis of activated CD4+ T cells towards CCL5 (50ng/ml) in the presence of 
lactic acid (10mM) or sodium lactate (10mM), shown as kinetic (left panel) and 4h time point (right 
panel). (G) Total cell number of viable CD4+ T cells treated with CXCL10 in the presence of lactic acid 
(10mM) or sodium lactate (10mM). (A-G) Values denote mean ± SD. (A) OA, n=5 and RA n=8 
(biological replicates, each measured in triplicate), (B-G) Data is representative of three independent 
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5.1.2 The effects of lactate on different T cell subsets are mediated by 
distinct transporters 
 
I next investigated the molecular basis of the differential and mutually exclusive 
responsiveness of CD4+ and CD8+ T cells to sodium lactate or lactic acid, 
respectively. Fischer et al. described the expression of SLC16A1 / MCT1 by human 
cytotoxic (CD8+) lymphocytes, a lactate - H+ symporter which facilitates lactic acid 
uptake (Fischer et al., 2007). SLC5A12 is the only sodium-coupled lactate 
transporter described so far (Srinivas et al., 2005). I found that murine CD8+ and 
CD4+ T cells selectively express SCL16A1 and SCL5A12, respectively (Figure 2A), 
suggesting a specific functional role of each transporter on the respective T cell 
subset.  
 
I subsequently sought to confirm that the differently expressed lactate transporters 
were functionally active in the inhibition of T cell chemokinesis. Blockade of 
SCL16A1 on CD8+ T cells with the selective small molecule inhibitors phloretin, CHC 
(Morris and Felmlee, 2008) and AR-C155858 (Ovens et al., 2010), restored 
chemokinesis of CD8+ T cells exposed to lactic acid (Figures 2B and 2C). The same 
effect was observed using a specific antibody targeting SCL16A1, yet not with an 
isotype control antibody (Figure 2B). Conversely, chemokinesis of CD4+ T cells in 
sodium lactate rich media was recovered following selective reduction of Slc5a12 
expression on CD4+ T cells with lentiviral delivered, specific shRNAs or a specific 
antibody (Figures 2D and 2E). The anti-SCL5A12 antibody or shRNAs targeting 
Slc5a12 did not affect CD8+ T cell migration (Figure 2F). Similarly, the SCL16A1 
inhibitors phloretin, CHC and AR-C155858 or the anti- SCL16A1 antibody did not 
affect the migration of CD4+ T cells (Figure 2G). 
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Figure  2 Sodium lactate and lactic acid act selectively on CD4+ and CD8+ 
T cell subsets through specific cell membrane transporters. 
(A) Total protein levels of the transporters SCL16A1 and SCL5A12 as assessed by western blot in 
activated CD4+ and CD8+ T cell subsets. (B–D) In vitro chemotaxis (4h time point) of activated CD8+ T 
cells towards CXCL10 (300ng/ml) in the presence of lactic acid (10 mM) alone, or in combination with 
CHC (425µM), phloretin (25µM), or anti-Slc16a1 antibody (2.5µg/ml) (B), or increasing concentrations 
of AR-C155858 as indicated in the figure (C), and activated CD4+ T cells towards CXCL10 (300ng/ml) in 
the presence of sodium lactate (10mM) alone, or in combination with an anti-SCL5A12 antibody 
(2.5µg/ml) or two specific shRNAs (D). An isotype control antibody has been included to control for 
antibody specificity (B, D), and a nonspecific shRNA has been included to control for gene knockdown 
specificity (D). (E) qRT-PCR and western blots with Slc5a12-specific primers and RNAs from activated 
CD4+ T cells expressing the shRNAs shown. 
Legend continued on next page 
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Figure 2 continued 
(F, G) In vitro chemotaxis (4 h time point) of activated CD8+ T cells towards CXCL10 in the presence of 
lactic acid (10mM) alone or in combination with an anti-SCL5A12 antibody (2.5µg/ml) or an isotype 
control antibody (B left panel) and two specific shRNAs for Slc5a12 or a nonspecific shRNA (B right 
panel), and activated CD4+ T cells towards CXCL10 in the presence of sodium lactate alone or in 
combination with CHC (425µM) or phloretin (25µM) (C left panel) and an anti-SCL16A1 (2.5µg/ml) or an 
isotype control antibody, or AR-C155858 (8nM) (C right panel) (B–G). Values denote mean ± SD. Data 
is representative of three independent experiments; n=3. *P<0.05; **P<0.01; ***P<0.001. 
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5.1.3 Lactate modulates effector T cell functions 
	  
Having established that extracellular lactate inhibits the migration of T cells, I next 
asked whether cytokine production and effector functions are also affected. I 
consequently induced polarization of CD4+ T cells towards Th1, Th2 and Th17 
subsets in the appropriate cytokine “milieus” (Fitch et al., 2006; Zhu et al., 2010). 
The expected patterns of cytokine expression by differentiated T helper subsets 
were confirmed at the mRNA level (Figure 3A). I then tested the effect of the 
presence of 10mM sodium lactate for 6 hours on the production of cytokines by the 
different T helper subsets in the same polarizing conditions. Gene expression 
analysis showed that treatment with sodium lactate caused a significant up-
regulation of Il17 in all the T helper subsets (Figure 3A). Supporting these data, 
gene expression of Rorc, the signature transcription factor of Th17 cells, was also 
significantly elevated in all the Th subsets upon T cell exposure to sodium lactate 
(Figure 3A). Gene expression of Th1 and Th2 signature cytokines was either 
unmodified upon treatment with sodium lactate or even reduced (i.e. Il4, Il5 and 
Il13 in the Th17 subset; Figure 3A). Intracellular staining experiments confirmed 
the increased expression of IL-17 protein in CD4+ T cells exposed to sodium lactate 
as compared to cells left untreated (Figure 3B). In support of this, pre-incubation 
with the antibody anti-SLC5A12 reduced the up-regulation of Il17 and Rorc genes 
induced by sodium lactate, yet not completely abolished it (Figure 3C). 
 
Cytotoxic T cells (CTLs) differentiating from the CD8+ subset express and release 
cytolytic granules consisting of perforin/granzyme complexes, which promote the 
killing of target cells (Metkar et al., 2002). To test whether these functions were 
affected by lactate, I performed cytotoxicity assays with allogeneic endothelial cells. 
Similarly to the results obtained in migration assays (Figure 1C), lactic acid but not 
sodium lactate inhibited the cytolytic activity of CTLs and promoted survival of the 
allogeneic target cells (Figure 3D) 
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Figure  3 Lactate modulates effector T cell function 
Lactate modulates effector T cell functions. (A) Relative mRNA expression levels of the cytokines Ifnγ, 
Tnfβ, Il4, Il5, Il13 and Il17 and of the transcription factor Rorc as assessed by qRT-PCR in CD4+ Th 
subsets Th0, Th1, Th2 and Th17 treated with sodium lactate (10mM) or left untreated. mRNA levels of 
each cytokine expressed by untreated Th0 cells were set to 1. (B) Intracellular staining of IL-17A and 
IFNγ in activated CD4+ T cells treated with sodium lactate (10mM) or left untreated. (C) Relative mRNA 
expression levels of Il17 and Rorc in activated CD4+ T cells treated with sodium lactate alone or in 
combination with an anti-SLC5A12 antibody. mRNA levels of untreated T cells were set to 1. (D) Cell 
survival of allogeneic endothelial cells in the presence of CD8+ cytotoxic T cells and lactic acid (10mM) or 
sodium lactate (10mM) shown as kinetic (left panel) and 6h time point (right panel). (A-D) Values 
denote mean ± SD. Data is representative of three independent experiments; n=3. *P<0.05; **P<0.01; 
***P<0.001. 
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5.2 CHAPTER II – METABOLIC CHANGES INDUCED BY LACTATE 
 
5.2.1 Lactate changes Redox state, acetyl-CoA and Citrate availability 
 
The lactate transporter specificity (Figure 2A) and the T cell insensitivity to lactate 
upon transporter inhibition (Figures 2B-D and 2F, G) suggest that the effects of 
lactate are mediated by intracellular signaling, possibly interfering with the cell 
metabolic machinery. One of the most prominent enzymes that act on lactate inside 
the cell is considered to be the cytoplasmic lactate dehydrogenase (LDH). The LDH 
functions as bidirectional enzyme either generating lactate from pyruvate with 
concomitant oxidation of NADH to NAD+ at high pyruvate concentrations or 
oxidizing lactate to pyruvate coupled to a reduction of NAD+ in the excess of lactate 
(Veech, 1991)(Equation 1). 
 
Equation 1 Lactate dehydrogenase reaction 
 
 
To test the involvement of the LDH, I measured the abundance of total NAD+ and 
NADH in activated CD4+ T cells exposed to 10mM sodium lactate. As expected, 10 
minutes after lactate addition, most of the available NAD+ was reduced to NADH as 
can be seen in a drastic drop in NAD+ levels compared to baseline, with 
simultaneous increase in NADH levels (Figure 4A). Surprisingly, after 30 minutes 
and up to 1h of lactate treatment the NADH levels fell back to baseline with only 
slight increase in NAD+, pointing towards a part re-oxidation and part biosynthetic 
use of NADH (Ying, 2008). Although NADH has many biological functions in the cell, 
a key function of NADH is to act as a cofactor in the NADH dehydrogenase / 
complex I of the mitochondrial electron transport chain (ETC). The ETC generates 
ATP and ROS during its activation (Finkel and Holbrook, 2000). In line with a 
mitochondrial oxidation of NADH, I found that the levels of ROS after 20 and 30 
minutes of lactate exposure were increased up to 3.5 and 2 fold respectively 
(Figure 4B). Interestingly, ROS levels transiently increased already after 5 minute 
exposure to lactate, which points to a secondary generation of ROS prior to the 
NADH dependent generation of mitochondrial ROS. Following the initial decrease in 
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NAD+ and NADH after 30 and 60 minutes, I found the levels of both oxidized and 
reduced NAD elevated after 2 and 6h respectively (Figure 4A). 
 
A possible fate of lactate is the oxidation to pyruvate via the LDH reaction, which 
will then enter the mitochondrial TCA cycle that generates a series of metabolic 
intermediates with the concomitant production of NADH molecules that fuel the 
ETC. I found two of these intermediates – acetyl-CoA and Citrate – to be elevated 
in activated CD4+ T cells after exposure to 10mM sodium lactate (Figure 4C-D). The 
amount of acetyl-CoA was elevated 2-fold after 10, 30 and 60 minutes, whereas 




Figure 4 Lactate changes abundances of intracellular metabolites 
Metabolite measurements of CD4+ T cells exposed to 10mM Sodium Lactate for different time points in 
(A) NAD+ / NADH depicted as % change compared to untreated (left) or ratio (right) and (B) Reactive 
oxygen species (ROS) compared to induction with 1mM H2O2. (C-D) Relative levels of acetyl-CoA (C) 
and Citrate (D) compared to untreated after Sodium lactate exposure. (A-D) Values denote mean ± SD. 
Combined data of four biological replicas; n=4. *P<0.05; **P<0.01; ***P<0.001. 
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5.2.2 Lactate decreases Glycolysis, Oxidative Phosphorylation and ATP 
levels  
 
The redox couple NAD+ / NADH as well as the metabolites acetyl-CoA and citrate 
are major regulators of cellular metabolism (Icard et al., 2012; Ying, 2008) and 
lactate itself has been shown to inhibit the rate limiting glycolytic enzyme 
Phosphofructokinase (Pfk) (Leite et al., 2011). To test the effect of extracellular 
lactate on metabolic activity, I measured glucose uptake and glycolytic flux using 
the fluorescent probes 2-NBDG and 6-NBDG in activated CD4+ and CD8+ T cells in 
the presence or absence of sodium lactate or lactic acid (Sukumar et al., 2013). 
Upon entering the cell 2-NBDG gets phosphorylated by hexokinase and rapidly 
degraded to non-fluorescent products. In contrast, 6-NBDG cannot be 
phosphorylated by hexokinase and accumulates in the cytoplasm in its fluorescent 
form. I could find that sodium lactate but not lactic acid selectively blocks glucose 
uptake and flux through glycolysis in CD4+ but not CD8+ T cells and vice versa, 
supporting the hypothesis of selective transporter dependent entry of lactate into 
these subsets (Figures 2A and 5A). 
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Figure 5 Metabolic changes induced by extracellular lactate 
(A) Measurements of glucose uptake and flux in activated CD4+ and CD8+ T cells pre-treated with 2-DG, 
sodium lactate or lactic acid and then incubated with the fluorescent probes 6-NBDG or 2-NBDG. (B, C) 
ECAR trace of glycolytic activity in activated CD4+ T cells treated with CXCL10 (1000ng/ml) and sodium 
lactate (10mM) in basal conditions with residual Glucose (B) or in the presence of 10mM Glucose (C). 
Vertical lines represent the addition times of CXCL10, sodium lactate or PBS. (D) Oxygen consumption 
rate (OCR) measurements in the of activated CD4+ T cells in the presence of 10mM Glucose and addition 
of 10mM Sodium Lactate (vertical line). (E) Relative levels of ATP compared to untreated after Sodium 
lactate exposure. (F) Time course western blots with antibodies against pAMPK, total AMPK, pACC and 
total ACC in activated CD4+ T cells treated with 10mM sodium lactate or left untreated. (G) Fatty acid 
oxidation (FAO) in CD4+ T cells in the presence of 2.5mM Glucose, 167µM BSA-palmitate or BSA alone. 
(A-G) Values denote mean ± SD. (A, B, F) Data is representative of three independent experiments; 
n=3. (C-E, G) Combined data of four biological replicas; n=4. *P<0.05; **P<0.01; ***P<0.001. 
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To support these data, I measured glycolytic flux with the seahorse extracellular 
flux analyzer in basal conditions with only minimal residual glucose present as well 
as in the presence of 10mM glucose. In both conditions I could find that injection of 
sodium lactate decreased the extracellular acidification rate (ECAR) of CD4+ T cells; 
in basal conditions from an average of 14 mpH/min in the untreated control to a 
level of less than 5mpH/min with lactate exposure (Figure 5B) and in the presence 
of glucose from 70mpH/min to 55mpH/min, confirming the observed decrease in 
glycolytic flux (Figure 5C). 
 
As lactate has been shown to serve as a fuel for oxidative phosphorylation in a 
number of cells, including neurons and muscle cells (Cornell et al., 1973; Kompanje 
et al., 2007; Magistretti et al., 1994), I measured the OCR of CD4+ T cells in the 
presence of 10mM sodium lactate, which is an indicator for mitochondrial activity. 
Surprisingly, also the OCR levels dropped from 220pmoles/min to 175pmoles/min 
within the first 20 minutes after injection, constituting a reduction of about 20% 
(Figure 5D). 
 
Glycolysis and oxidative phosphorylation are two of the major ATP producing 
pathways in the cell. In line with the lactate-mediated inhibition of glycolysis and 
oxphos, also the ATP levels decreased 25% in the first 10 minutes and further fell 
down to 50% of the original value in the first half hour after lactate exposure 
(Figure 5E). A drop in ATP levels is a major activation signal for 5’-AMP activated 
protein kinase (AMPK), a master regulator for cellular homeostasis (Hardie et al., 
2012). 30 minutes after sodium lactate exposure, I found AMPKα phosphorylated 
on Threonin 172 residue, which is a signal for its activation (Figure 5F). A 
downstream target of AMPK is the acetyl-CoA-Carboxylase (ACC), the rate-limiting 
enzyme for fatty acid synthesis (FAS) (Donaldson, 1979). Supporting the ATP and 
AMPK data, I also could detect phosphorylated ACC at Serin 79, up to 6h after 
lactate exposure, with no phosphorylation detectable at 12h and 24h (Figure 5F).  
 
ACC phosphorylation inhibits its enzymatic activity and consequently the synthesis 
of fatty acids (Park et al., 2002). ACC catalyzes the carboxylation of acetyl-CoA to 
form malonyl-CoA, the main molecular precursor for fatty acid synthesis. When FAS 
is activated, malonyl-CoA also acts as an inhibitor for mitochondrial β-oxidation as 
it inhibits carnitine palmitoyl transferase 1a (CPT1a) by direct interaction and thus 
the transport of fatty acids into the mitochondrial matrix (Foster, 2012). I thus next 
tested whether lactate could also interfere with lipid metabolism and shift the 
metabolic program to the oxidation of fatty acids (FAO). I measured OCR in the 
presence of 2.5mM glucose and 1µM BSA-palmitate that served as a substrate for 
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FAO. The treatment with BSA alone reflects the oxphos mediated oxygen 
consumption, which I found comparable with previous measurements (Figure 5D 
and 5G) (Gerriets et al., 2015). The addition of BSA-palmitate raised the oxygen 
consumption significantly in the untreated and in the 4h sodium lactate treatment 
cells, indicating that the basal rate of exogenous FAO is not affected by lactate 
(Figure 5G). In order to measure the oxidation of endogenous fatty acids, I used 
the CPT1a inhibitor Etomoxir that blocks the uptake of FA (Schoors et al., 2015) 
into the mitochondria. Interestingly, no detectable difference between lactate 
treatment and control cells could be seen (Figure 5G). 
 
To sum up, I could find that the presence of 10mM extracellular sodium lactate 
reduced the level of glycolysis, oxidative phosphorylation and consequently ATP 
levels, yet left fatty acid metabolism unaltered. It is tempting to conclude that high 
concentration of lactate represents a signal for the induction of FAO in order to 
rescue the metabolic breakdown of glycolysis and oxphos. This hypothesis is in 
accord with the recent detection of LDH in the peroxisomes, which represents a 
central organelle in fatty acid metabolism (Schueren et al., 2014). 
 
5.2.3 Changes in global acetylation and PARylation patterns induced by 
sodium lactate 
 
The availability of reduced and oxidized NAD has wide-reaching effects on cellular 
metabolism, as it is an essential cofactor of many biochemical reactions and so a 
central regulator of metabolic activity (Ying, 2008). One of the main NAD+ 
dependent enzyme classes are the sirtuins, a family of histone deacetylases 
(HDACs), that are involved most prominently in regulating mitochondrial 
metabolism, aging, and mediate the effect of calorie restriction (Canto and Auwerx, 
2009). Sirtuins most commonly ADP-ribosylate acetyl-lysine residues of acetylated 
proteins leading to their reversible deacetylation (Yang et al., 2006). The ability to 
deacetylate proteins is believed to be of great importance in the mitochondria, 
which contain abnormally high levels of NAD, which correlates with a relatively low 
number of acetylated proteins and normal mitochondrial function (Kim, 2006). In 
the absence of mitochondrial Sirt3, mitochondrial proteins become hyperacetylated, 
which leads in turn to mitochondrial dysfunction, which is a common phenomenon 
of age and -related diseases (Anderson and Hirschey, 2013). To test for activity of 
sirtuins, I probed whole cell protein lysates with an antibody that detects acetylated 
lysine residues. In the first 6h of sodium lactate treatment, I could not find any 
major changes in whole cell lysine acetylation, yet a shift in the band pattern 
occurred at later timepoints (12h, 24h) (Figure 6A). 
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Another class of NAD+ dependent enzymes are the Poly (ADP-Ribose) polymerases 
that catalyze the polymerization of ADP-Ribose from NAD+ onto a protein, attaching 
linear branched polypeptides (Kim et al., 2005). This PARylation plays significant 
roles in many cellular and molecular mechanisms, including DNA repair, apoptosis, 
chromatin modifications or mitosis (Kim et al., 2005).  
 To detect global changes in protein PARylation I used an antibody that detects 
ADP-ribose polymers. Interestingly, I again could find only minor changes in the 
PARylation pattern in the first 6h of lactate exposure, yet a complete absence of 
PARylated proteins upon 12h and 24h of treatment (Figure 6B). This absence of 
PARylation reflects lactate-induced inhibition of one or more PARP family members 
after 12h and 24h of lactate exposure (Kim et al., 2005). 
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Figure  6 Sodium lactate induces changes in the cellular protein acetylation 
and parylation pattern. 
(A) Western blot of whole CD4+ T cell lysates exposed for different times to 10mM Sodium lactate and 
probed with antibodies against total Lysine-Acetylation (K-Ac) or PARylation (B). Data is representative 
of three independent experiments; n=3. Western blots in (A) and (B) are done on the same membrane. 
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5.3 CHAPTER III – THE BIOCHEMICAL BASIS FOR LACTATE-MEDIATED 
PHENOTYPE CHANGES 
 
5.3.1 CXCL10 - Chemokine signaling induces Glycolysis in CD4+ T cells 
 
In order to find the metabolic basis and connect the biochemical alterations 
(Chapter II) to the observed defect in migration described in Chapter I, I started by 
investigating the effect of CXCL10 treatment on the induction of glycolysis in CD4+ 
and CD8+ T cells activated for 3 days with anti-CD3 and anti-CD28 antibodies and 
interleukin-2 (IL-2). I found that hexokinase 1 (HK1) and pyruvate kinase (PK) M2, 
two rate-limiting enzymes in the glycolytic pathway, were up-regulated at protein 
level in CD4+ T cells at 2h and 4h after CXCR3 receptor engagement with CXCL10 
respectively (Figure 7A). In contrast, CD8+ T cells did not undergo major changes 
in the expression of glycolytic proteins upon exposure to CXCL10 (Figures 7B). 
 
Additionally, mRNA levels of Hk1, PkM2 as well as glucose transporters Glut1-4 
were also up-regulated 6h after treatment with CXCL10 in CD4+ T cells, yet I could 
only find Glut1 and Glut3 up-regulated in CD8+ T cells (Figures 7C and 7D) (Finlay, 
2012). These findings suggest the existence of multiple regulatory mechanisms of 
the glycolytic pathway downstream of CXCR3 signaling, including transcriptional 
and post-translational control. Also, the discrepancy between CD4+ and CD8+ T 
cells to up-regulate glycolytic enzymes after CXCR3 engagement, points towards a 
differential regulation and metabolic requirement for chemokinesis in these subsets 
(Wahl et al., 2012). 
 
Surprisingly, treatment of CD4+ T cells with CXCL10 in the presence of sodium 
lactate resulted in the reduction of HK1 levels as compared to CD4+ T cells treated 
with CXCL10 alone (Figure 7A). This effect could not be observed in CD8+ T cells 
treated with CXCL10 and lactic acid, supporting the notion of differential metabolic 
requirements and control of migration (Figure 7B). 
 
Glycolytic metabolism has recently been shown to be able to respond within 
milliseconds of engaging an extracellular signal (Barros et al., 2013) and these 
rapid changes are commonly regulated by enzymatic activities (Berg et al., 2007). I 
therefore tested whether CXCL10 also increases the level of glycolytic flux upon 
engagement with its receptor CXCR3. Exposing CD4+ T cells to the chemokine 
raised the ECAR value from 13mpH/min to about 18mpH/min, indicating that the 
glycolytic flux is increased in these conditions (Figure 7E). I then asked whether the 
presence of sodium lactate was able to diminish this glycolytic increase also upon 
CXCR3 engagement by CXCL10, similarly to what had I observed previously 
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(Figures 5A-C) (Sidahmed et al., 2012). Adding sodium lactate to the CXCL10-
stimulated cells decreased basal glycolysis to similar levels as detected with sodium 
lactate alone (Figure 5B), as reflected by a drastic fall of ECAR (Figure 7E). This 
suggests a dominant effect of lactate over CXCR3 signaling. The oxygen 
consumption rate was not affected by the addition of the CXCR3 ligand, yet it 
decreased about 25% within the first 20 minutes after sodium lactate treatment, 
confirming some of my initial findings (Figures 7F and 5D).  
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Figure 7 CXCL10 induces glycolysis 
(A, B) Western blots with antibodies against HK1, PKM1/2, ALDO A, ENO1 and β-ACTIN in activated 
CD4+ (A) or CD8+ T cells (B) treated with CXCL10 (1000ng/ml) alone or in combination with sodium 
lactate (10mM) (A), lactic acid (B), or left untreated. (C, D) Relative mRNA expression levels of Hk1, 
PkM2 and glucose transporters (Glut1, Glut2, Glut3, Glut4) in activated CD4+ (C) or CD8+ (D) T cells 6-
hours post-treatment with CXCL10 (1000ng/ml) as assessed by qRT-PCR. mRNA levels in naïve, resting 
CD4+ T cells were set to 1. (E) ECAR trace of glycolytic activity expressed as mpH/min in activated CD4+ 
T cells treated with CXCL10 (1000ng/ml), sodium lactate (10mM) or PBS. (F) Corresponding OCR trace 
of CD4+ T cells treated with CXCL10 (1000ng/ml), sodium lactate (10mM) or PBS. Vertical lines 
represent addition times of CXCL10, sodium lactate or PBS. (A, B) Densitometric quantification of 
western blots denotes mean ± s.e.m., n=3 (biological replicates, each run in duplicate). (C-F) Data is 
representative of three independent experiments. *P<0.05; **P<0.01; ***P<0.001. 
 
70 / 123 
	  
 
5.3.2 Basal and chemokine-induced glycolysis is required for CD4+ T cell 
migration both in vitro and in vivo 
 
The finding that sodium lactate inhibits both glycolysis and oxidative 
phosphorylation in CD4+ T cells (Figure 5A-E) but has no effect on FAO (Figure 5G) 
and CXCR3 signaling induces glycolysis specifically (Figure 7A-C and 7F), suggests 
that glycolysis is required for CD4+ T cell migration. 
 
To test this hypothesis, I treated activated CD4+ T cells with inhibitors or activators 
of glycolysis and assessed their chemokinetic responses to CXCL10. Direct or 
indirect inhibition of glycolysis with the glucose analogue 2-DG or mTOR inhibitor 
rapamycin caused a decrease in chemokinesis in vitro (Figure 8A) and in a well-
established in vivo model of T cell recruitment to the peritoneum (Figures 8B and 
8G) (Jarmin et al., 2008). 
 
Conversely, activation of glycolysis using the electron transfer chain Complex I 
inhibitor and AMPK activator metformin (Figure 8E and 8F) (Buzzai et al., 2007; 
Delmastro-Greenwood and Piganelli, 2013; Doherty et al., 2014; Yi et al., 2013), 
increased chemokinesis to CXCL10 both in vitro and in vivo (Figures 8A and 8B). 
Accounting for the specificity of the glycolytic measurements, etomoxir, an inhibitor 
of CPT1a and hence FAO, had only minor effects on glycolysis (Figure 8E). 
 
In addition, metabolic drugs interfering with glycolysis had similar effects on T cell 
motility in spontaneous migration assays that are independent of any pro-
inflammatory chemokine stimulus, implying the role of this pathway in steady-state 
control of T cell migration (Figure 8C). Importantly, exposure to the various 
metabolic drugs at the concentrations used did not affect the T cell surface 
molecule phenotype and receptor expression (Figure 8H and 8I), supporting the 
hypothesis that cell intrinsic metabolic mechanisms regulate the migration of T 
cells. 
 
The importance of aerobic glycolysis in the activation and function of T cells has 
been shown previously (Chang et al., 2013; Gerriets and Rathmell, 2012; Michalek 
et al., 2011), yet its potential impact on naïve T cell migration is still unexplored. I 
therefore assessed the influence of glycolysis on migration of naïve T cells, which 
mainly rely on oxidative metabolism for their homeostasis (Gerriets and Rathmell, 
2012). Similar to what I had observed in activated T cells, inhibition of glycolysis 
via 2-DG and rapamycin resulted in a decrease in naïve T lymphocyte migration 
towards the homeostatic chemokines CCL19/21 (Figure 8D), suggesting a general 
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control of T cell migration via the glycolytic pathway. In contrast to activated T 
cells, however, exposure to metformin reduced naïve T cell migration (Figure 8F), 
indicating the existence of different metabolic checkpoints between naïve and 
activated T cells (Wang and Green, 2012). 
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Figure 8 Basal and chemokine-induced aerobic glycolysis is required for 
CD4+ T cell migration 
(A) In vitro chemokinesis (4 hour time-point) towards CXCL10 (300ng/ml) of activated CD4+ T cells pre-
treated with Rapamycin (200nM), 2-DG (1mM) or Metformin (2mM). (B) Relative enrichment of i.v. 
injected activated CD4+ T cells pre-treated with Rapamycin (200nM), 2-DG (1mM) or Metformin (2mM) 
and subsequently labelled with DDAO cell fluorescent dye in the peritoneal lavage of syngeneic recipient 
C57BL/6 mice i.p. injected with CXCL10 (120ng/mouse). (C) Spontaneous trans-endothelial migration (6 
hour time-point) of activated CD4+ T cells in the presence of rapamycin (200nM), 2-DG (1mM) or 
metformin (2mM). 
Legend continued on next page 
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Figure 8 continued 
(D) In vitro chemotaxis (4 h time point) towards the chemokines CCL19/21 (200 ng/ml of each 
chemokine) of naïve T cells pretreated with Rapamycin (200nM), 2-DG (1mM) or Metformin (2mM). (E) 
ECAR trace of glycolytic activity expressed as mpH/min and corresponding OCR trace (F) in activated 
CD4+ T cells treated with 2-DG (1mM), Rapamycin (200nM), Metformin (2mM) or Etomoxir (40µM). (G) 
Representative FACS dot plots of DDAO-labelled donor CD4+ T cells collected from the peritoneal lavage 
and spleen of recipient mice, which correspond to the relative enrichment in peritoneal lavage shown in 
Fig 8B. (H) In vitro chemokinesis (4 hour time-point) towards CXCL10 (300ng/ml) of activated CD4+ T 
cells in the presence of sodium lactate pre-treated with Ex-527 (1µM) or PJ-34 (25µM). 
Legend continued on next page 
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Figure 8 continued 
(I) Representative FACS dot plots and histograms showing cell surface expression of CD4, CD8, and 
CD25 on activated T cells treated with Rapamycin (200 nM), 2-DG (1 mM) or Metformin (2 mM) as 
assessed by flow cytometry. (J) Representative FACS dot plots and histograms showing FSC/SSC profile 
and cell surface expression of CXCR3, CCR7, CD62L, and LFA-1 on activated T cells treated with 
Rapamycin (200nM), 2-DG (1mM) or Metformin (2mM) as assessed by flow cytometry. Data is 
representative of three (A, C, D, H) or two (E, F) independent experiments. (B) n=4 biological 
replicates. *P<0.05; **P<0.01; ***P<0.001. 
 
 
To substantiate my hypothesis that glycolysis is necessary for the migration of 
activated CD4+ T cells and to determine the relative contribution of NAD 
metabolism to the migratory phenotype (Hurd et al., 2012), I tested inhibitors of 
SIRT1 and PARP1, the major isoforms of sirtuins and poly (ADP-Ribose) 
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polymerases in the cell (Ba and Garg, 2011; Finkel et al., 2009). Ex-527 is a 
specific inhibitor of SIRT1 activity at the used concentration (Gertz et al., 2013) 
and PJ-34 is commonly used to inhibit PARP1 activity (Huang et al., 2008; Sajish 
and Schimmel, 2015). The sole inhibition of SIRT1 or PARP1 did not affect the 
chemokinesis in response to CXCL10, yet either of them could rescue the migration 
inhibition in the presence of sodium lactate (Figure 8H). This suggests that a 
crosstalk or a competition for NAD+ between SIRT1 and PARP1 (Chung and Joe, 
2014) could potentially exert the effects of the sodium lactate mediated migratory 
inhibition of CD4+ T cells, dependent on glycolytic metabolism. A recent publication 
from Fouquerel et al. (2014) partly supports this hypothesis as they show that 
activation of PARP1 negatively regulates HK1 activity that causes a reduction in 
glycolysis and ATP levels, similarly to what I had observed (Figure 7A, 5A-C and 
5E) (Fouquerel et al., 2014). 
 
To conclude, I could find that glycolysis positively regulates the migration of CD4+ T 
cells, which leads to the suggestion that the lactate mediated glycolytic decrease 
might as well be responsible for the observed migratory phenotype. Although the 
exact mechanism is not yet completely elucidated, the activity of the metabolic 
regulators SIRT1 and PARP1 seems to play a role. In this context it is interesting to 
notice that the activity of both SIRT1 and PARP1 have previously been linked to cell 
migration by interaction with cytoskeletal scaffold proteins (Cavone et al., 2011; 
Tang, 2010; Zhang et al., 2009). 
 
 
5.3.3 Lactate exposure causes metabolic adaption in CD4+ T cells 
 
Next, I started to investigate how T cells adapt their metabolism in response to the 
exposure to extracellular lactate (Figure 5). First, I sought to confirm the sodium 
lactate-mediated decrease of HK1 protein (Figure 7A), which could provide an 
explanation for the detected decrease in glycolytic flux. I used confocal microscopy 
of lactate-treated CD4+ T cells to assess the co-localization of HK1, mitochondria 
(MitoTracker) and nucleus (DAPI). Interestingly I could find that a 4 hour treatment 
with sodium lactate caused a relocation of HK1 from the cytosol to the mitochondria 
(Figure 9A) rather than a decrease in protein level (Figure 7A) (John et al., 2011). 
In order to investigate this discrepancy further I performed cell compartment 
isolation to enrich for cytosolic, mitochondrial and nuclear proteins of cells exposed 
to lactate with subsequent detection. 
 
To analyse the purity of the enriched cellular compartments, I probed for the 
predominantly cytosolic, mitochondrial and nuclear proteins β-Actin, Pyruvate 
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Dehdrogenase (PDH) and Histone H3 respectively. Although I could detect some 
residual Histone H3 proteins also in cytosolic and mitochondrial fraction, the other 
isolated cell compartments were pure. 
 
Confirming the microscopy data, I found a slight increase in mitochondrial enriched 
HK1 after 4 hour lactate compared to untreated cells (UT, Figure 9B left, John et 
al., 2011). A concurrent decrease in cytosolic HK1 levels in the lactate treated cells 
supports the hypothesis that lactate causes a translocation rather than degradation 
of HK1 to the mitochondria in line with previous observations (Neupert and 
Herrmann, 2007; Schindler and Foley, 2013). Interestingly, this translocation could 
only be detected for Hk1 and not another glycolytic enzyme PkM1/2 or the 
metabolic enzyme PARP1. Increased mitochondrial localization of HK1 is commonly 
associated with higher glycolytic flux that has been suggested to be due to 
increased availability of mitochondrial derived ATP (Wilson, 2003). Consistent with 
this hypothesis and confirming my previous data, I found glycolytic flux 4h after 
lactate treatment to be at the same level as in the untreated cells after an initial 
reduction in the first hour (Figure 9C). 
 
Strikingly, 12 hours after lactate treatment the glycolytic flux was again reduced of 
about a third of the initial value, which aligned with a similar decrease in basal and 
maximum mitochondrial oxidative phosphorylation (Figures 9C and 9D). 
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Figure 9 Metabolic adaption in CD4+ T cells exposed to sodium lactate 
(A) Confocal images of CD4+ T cells untreated (left) or exposed to 4h sodium lactate (10mM), stained 
with DAPI, anti-HK1 antibody or MitoTracker Deep Red FM (300nM). (B) Western blots of cytosolic (C), 
mitochondrial (M) or nuclear (N) fractions of activated CD4+ with sodium lactate (10mM), detected with 
antibodies against HK1, PARP1, PKM1/2, PDH, β-ACTIN and Histone H3. (C) Glycolytic ECAR 
measurement in mpH/min of CD4+ T cells in the presence of 10mM Glucose and 10mM Sodium lactate. 
(D) Metabolic stress test analysis of CD4+ T cells after 12h exposure to 10mM sodium lactate; ECAR 
trace (left) and OCR (right). (E) Relative mRNA expression of gluconeogenesis genes Pck1, Pck2, Fbp1, 
Pparγ, Pgc1α and G6Pc in activated CD4+ T cells exposed to 12h sodium lactate (10mM). mRNA levels in 
activated, resting CD4+ T cells were set to 1. Data is representative of two (A) or three (B) independent 
experiments. (C-E) n=4 biological replicates. *P<0.05; **P<0.01; ***P<0.001. 
 
 
Lactate can be utilized as a fuel source to generate glucose during the liver-muscle 
Cori cycle, so I next tested whether similar mechanisms might be at play here as 
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well. As reported in L6 muscle cells (Hashimoto et al., 2007), I could also find 
genes regulating gluconeogenesis up-regulated (Figure 9E). Amongst these were 
rate-limiting enzymes Pyruvate carboxykinase 1 (Pck1), Fructose-Bisphosphatase 1 
(Fbp1), the glucose-forming enzyme Glucose-6-Phosphatase (G6pc) and the master 
transcription factors of gluconeogenesis Pparα and Pgc1α (Herzig et al., 2001; 
Patsouris et al., 2004; Yoon et al., 2001). 
 
These data point towards a short-term metabolic adaption of CD4+ T cells exposed 
to lactate to cope with the initial biochemical breakdown of glycolysis and 
mitochondrial oxphos and furthermore a long term adaptation towards 
gluconeogenesis in order to use extracellular lactate as an alternative fuel source 
(Cornell et al., 1973; Magistretti et al., 1994). 
 
5.3.4 Sodium lactate induced IL-17 expression is dependent on NAD 
metabolism, FAS and Foxo1 
 
Having established that a sodium lactate dependent decrease in glycolysis is the 
causative link to the observed migratory inhibition, possibly exerted via Sirt1 and 
Parp1, I next asked whether this glycolytic inhibition also causes the increase in IL-
17 production (Figures 3A and 3B) (Shi et al., 2011; Yabu et al., 2011). I hence 
tested the effect of the glycolytic inhibitors 2-DG and Rapamycin as well as AMPK 
activator metformin on the production of IL-17. Surprisingly, both glycolysis 
inhibition and activation with the drugs caused a 75% increase in IL-17 protein 
secretion (Figure 10A middle), whereas sodium lactate only caused 40% more 
production (Figure 10A, left). These data suggest that the lactate-mediated 
inhibition of glycolysis is not the sole cause for the observed cytokine secretion. 
 
As metformin is an inhibitor of the complex I within the ETC and only indirectly 
activates glycolysis via AMPK, which is activated due to a drop in ATP levels 
(Figures 5E and 5F) (Mihaylova and Shaw, 2011), I next tested the involvement of 
oxidative metabolism in the production of IL-17. Treating the cells with either the 
ATP synthase (complex V) inhibitor Oligomycin A (Shchepina et al., 2002), the 
mitochondrial uncoupler FCCP (Benz and McLaughlin, 1983), complex I or III 
inhibitors Rotenone (Li et al., 2003) and Antimycin A (Ma et al., 2011) respectively, 
did not cause any significant increase in the release of IL-17 (Figure 10A, right). 
These results indicate that the observed drop in oxphos after lactate exposure 
(Figure 5D) is not involved in the increased generation of the pro-inflammatory 
cytokine IL-17 and that additional parallel mechanisms might play a role. 
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To further identify the molecular pathways involved in the observed functional 
phenotype, I assessed whether the increase in IL-17 I could detect in the treatment 
with the glycolytic drugs (Figure 10A) is due to a transcriptional activation of the 
IL-17 gene. However, none of the used compounds showed a regulation at the 
mRNA level, which points towards a translational or post-translational mechanism 
in the regulation of 2-DG-, rapamycin- or metformin-mediated IL-17 secretion 
(Figure 10B, left) (Noubade et al., 2011) that is independent from the reported 
lactate induced effect (Figure 9B, left). Oxamate however, an additional glycolytic 
inhibitor that targets the LDH (Novoa et al., 1959), increased IL-17 mRNA on its 
own and rescued the sodium lactate dependent increase (Figure 10B, left), placing 
the biochemical reactions exerted by the LDH in the spotlight. 
 
The involvement of LDH (Figure 10B, left) and the change in NAD+ / NADH levels 
caused by sodium lactate (Figure 4A), led me to hypothesize that a lactate-induced 
change in the redox state leads to the production of IL-17. This hypothesis is 
supported by several reports that identify redox changes as regulators of cytokine 
production (Alam et al., 2010; Haschemi et al., 2012; Kesarwani et al., 2013). As 
previously, I used the SIRT1 inhibitor Ex-527 and the PARP1 inhibitor PJ-34 to test 
for their involvement. I noticed that not exclusive inhibition of Sirt1, but inhibition 
in the presence of sodium lactate could rescue the phenotype (figure 10B, middle). 
Similarly, PARP1 inhibition could also rescue IL-17 production by sodium lactate, 
yet on its own imitated the effect seen by sodium lactate alone (Figure 10B, 
middle). These data infer that the sodium lactate mediated transcription of IL-17 
requires the activation of SIRT1 that might be dependent on the inhibition of PARP1 
(Bai et al., 2011), as I had observed previously (Figures 6a and 6B). 
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Figure  10 Lactate mediated IL-17 expression depends on NAD 
metabolism, FAS and Foxo1 
(A) IL-17A ELISA from supernatants of activated CD4+ T cells treated overnight with sodium lactate and 
metabolic drugs Rapamycin (200nM), 2-DG (1mM), Metformin (2mM). (B) Relative Il17 mRNA 
expression of activated CD4+ T cells treated with inhibitors or activators of glycolysis and oxphos (left), 
NAD metabolism and Foxo1 (middle) or Hif1α (right) in the presence or absence of 10mM Sodium 




To find transcription factors that might be involved in the sodium lactate mediated 
IL-17 production, I tested the involvement of metabolic master regulators such as 
FOXO1, which has already been shown to influence the production if IL-17 and 
generation of Th17 cells (Ouyang et al., 2010). The FOXO1 inhibitor AS1842856 
could normalize IL-17 mRNA levels in the presence of sodium lactate without showing 
effects on its own, proving the importance and involvement of FOXO1 in the lactate-
stimulated IL-17 induction (Figure 10B) (Laine et al., 2015; Wu et al., 2013).  
 
Extracellular lactate is a known inducer of hypoxia (De Saedeleer et al., 2012; 
Sonveaux et al., 2008), a cellular response regulated by HIF1α. Recently, HIF1α could 
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be shown to be indispensable for the generation of Th17 cells (Dang et al., 2011; Shi 
et al., 2011), so I investigated the possible role of this transcription factor in my 
settings. Two known inducers of hypoxia and HIF1α, Desferrioxamine (DFO) (Woo et 
al., 2006) and Cobalt Chloride (CoCl2) (Piret et al., 2002; Yuan et al., 2003) showed 
different effects on the induction of IL-17 (Figure 10B, right). Similarly, of the known 
Hif1α inhibitors TOFA and C75 (Berod et al., 2014), only TOFA could inhibit the 
induction of IL-17 mediated by sodium lactate (Figure 10B, right). These results point 
to the conclusion that although HIF1α has been shown to be important for the 
generation of TH17 cells (Shi et al., 2011) and the production of IL-17 in certain 
conditions (Dang et al., 2011), it possibly only plays a secondary role in the generation 
of IL-17 downstream of sodium lactate. Interestingly, TOFA activates Hif1α via 
inhibition of ACC, the rate-limiting enzyme of fatty acid synthesis (FAS) that I have 
earlier shown to be activated after 12h and 24h of lactate exposure (Figure 5F) and 
which has recently been reported to be essential for the induction of Th17 cells (Berod 
et al., 2014). 
To sum up, I could exclude the direct involvement of either glycolysis or oxphos in the 
generation of sodium lactate dependent IL-17. I however identified FOXO1, ACC and 
SIRT1 activity as to be mediating the effects of sodium lactate on IL-17 expression. 
Implications and further direction will be discussed in a later chapter. 
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5.4 CHAPTER IV – THERAPEUTIC ASPECTS 
 
Having established that accumulating extracellular lactate has widespread 
metabolic effects on T cells that lead to the inhibition of migration and secretion of 
the pro-inflammatory cytokine IL-17, I next interrogated the possible therapeutic 
implications of my findings. 
 
5.4.1 Lactate signaling in Rheumatoid Arthritis 
 
I have shown that in humans the synovial fluid of rheumatoid arthritis (RA; 
inflammatory form of arthritis) contains elevated levels of lactate compared to the 
non-inflammatory types (e.g. osteoarthritis [OA], Figure 1A). The rheumatoid 
synovial environment is paradigmatic of some of the lactate-induced changes seen 
in T cells, including entrapment, IL-17 secretion and loss of antigen responsiveness 
(Croia et al., 2013). I therefore investigated the expression and cellular localization 
of the lactate transporters SLC5A12 and SLC16A1 of 16 patients suffering from RA 
and undergoing total joint replacement therapy (Table 1, demographical data). I 
first stratified RA patients for the amount of CD3+ infiltrating T cells using a semi-
quantitative score (Figure 11A) as described in (Croia et al., 2013). Hereby, the 
CD3 score increases with the amount of T cell infiltrates. 
 
I then performed gene expression analysis on total RA synovial tissue and found 
that SLC5A12 mRNA expression significantly increased in correlation with the T cell 
score of the samples tested (Figure 11B). Albeit not significant, a trend towards 
increased SLC16A1 expression could also be observed in CD8+ T cells (Figure 11B, 
left). 
 
In order to confirm my in vitro data that SLC5A12 is expressed on CD4+ but not 
CD8+ T cells (Figure 2A), I performed double immunofluorescence microscopy for 
SLC5A12 and either CD4 or CD8. As shown in Figure 11C, SLC5A12 is abundantly 
and selectively expressed by CD4+ but not CD8+ T cells within the RA synovial 
tissue. Additionally, CD4+ and CD8+ T cells isolated from the peripheral blood of 
human healthy donors responded in vitro to sodium lactate and lactic acid similarly 
to their murine counterparts in terms of migration (Figure 11D) and expression of 
IL-17 protein (Figure 11E). 
 
These findings establish lactate signaling as integral feature of RA and open up the 
possibility of targeting lactate for therapeutic intervention. 
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Figure  11 Lactate signaling in human RA 
(A) Representative images of RA synovial tissues stained for CD3 displaying progressively higher degree 
of T cell infiltration as quantified using a semi-quantitative score from T0 (absence of infiltrating T cells) 
to T3 (large number of infiltrating T cells organizing in ectopic follicles). (B) Relative mRNA expression 
levels of SLC16A1 and SLC5A12 in the synovial fluid isolated from the joints of RA patients. Samples are 
grouped based on their T cell score as described in A. Values denote mean ± s.e.m., (T0) n=6 and (T2-
3) n=9 (biological replicates, each measured in triplicate). *P<0.05. (C) Double immunofluorescence 
staining for SLC5A12 and CD4 or CD8 in the synovial tissue of RA patients. SLC5A12 (green) is highly 
expressed within the RA synovium in the presence of a high degree of CD4+ (red) T cell infiltration. 
Merging (yellow) of the green and red channels demonstrates that SLC5A12 is selectively expressed by 
CD4+ but not CD8+ infiltrating T cells. Quantification of the % double positive cells is provided upon 
counting positive cells (single and double positive for each marker) in 6 images per condition. Columns 
represent % of double positive CD4+ SLC5A12+ population within the CD4+ or SLC5A12+ cells and % of 
double positive CD8+ SLC5A12+ population within the CD8+ or SLC5A12+ cells. Scale bars: 50 µm. (D) In 
vitro chemokinesis (4h time point) of activated human CD4+ and CD8+ T cells towards CXCL10 
84 / 123 
	  
(300ng/ml) in the presence of lactic acid (10mM) or sodium lactate (10mM). (E) Intracellular staining of 
IL-17A in activated human CD4+ T cells treated with sodium lactate (10mM) or left untreated. (D, E) 





5.4.2 Inhibition of lactate transporters promotes the release of T cells 
from the inflamed tissue 
	  
I next sought to assess whether lactate promotes the retention of T cells in 
inflammatory sites in vivo and whether inhibitors of the lactate transporters favor 
the release of T cells from the inflamed site. I used a well-established mouse model 
of zymosan-induced peritonitis, in which T cells are recruited to the inflamed site 5 
days after zymosan injection (Montero-Melendez et al., 2011). C57BL/6 mice were 
injected in the peritoneal cavity with zymosan (1mg/mouse) or left untreated. Five 
days later, Phloretin, an anti-SLC5A12 antibody or an isotype control antibody were 
injected into the peritoneal cavity. After 24h, mice were sacrificed and the 
peritoneal lavage was harvested. Lactate levels and CD4+ and CD8+ T cells were 
increased significantly in the peritoneum of recipient animals (Figures 12A and 12 
B). Intraperitoneal injection of anti-SLC5A12 antibody caused a significant reduction 
of CD4+ T cells in the peritoneum in comparison to an isotype-matched control 
antibody, while having no effect on CD8+ T cells (Figures 12B and 12D-E). In 
contrast, phloretin promoted a significant decrease of CD8+ T cells in the 
peritoneum but did not show any effect on CD4+ T cells (Figures 12B and 12D-E). 
 
To establish that the decrease in T cell localization to the peritoneal cavity was at 
least in part due to their increased release from this site, I performed adoptive 
transfer experiments whereby CFSE-labeled CD4+ T cells were co-injected with 
anti-SLC5A12 antibody, phloretin or an isotype control antibody in the peritoneal 
cavity of mice which had been injected with zymosan (1mg/mouse) 5 days before, 
to create an environment rich of lactate (Figure 12A). 24 hours after the intra-
peritoneal injection of CFSE-labeled CD4+ T cells the mice were sacrificed and 
peritoneal lavage and spleen were harvested. I found that injection with anti-
SLC5A12 antibody but not phloretin or the isotype control antibody in the peritoneal 
cavity caused a selective reduction of adoptively transferred T cells in the 
peritoneum and their accumulation in the spleen (Figures 12C and 12F). 
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Figure 12 Inhibition of lactate transporters releases T cells from inflamed 
peritoneum 
(A) Lactate levels in the peritoneum of zymosan-treated mice. (B) Number of CD4+ and CD8+ T cells, 
respectively, in the peritoneal lavage of C57BL/6 mice injected i.p. with zymosan (1mg/mouse) to 
induce peritonitis, and 5 days later i.p. treated with Phloretin (50µM), an anti-SLC5A12 antibody 
(5µg/ml) or an isotype control antibody. (C) Number of CFSE-labeled activated CD4+ T cells in the 
peritoneal lavage (left panel) or spleen (right panel), respectively, of C57BL/6 mice injected i.p. with 
zymosan (1mg/mouse), then i.p. treated with Phloretin (50µM), an anti-SLC5A12 specific antibody 
(5µg/ml) or an isotype control antibody. 
Legend continued on next page 
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Figure 12 Continued 
(D, E) Representative peritoneal lavage FACS dot plots of activated CD4+ (D) and CD8+ (E) T cells of 
C57BL/6 mice injected i.p. with zymosan to induce peritonitis, and 5 days later treated with SLC5A12 
specific antibody (5µg/ml), phloretin (50µM) or isotype control antibody, which correspond to the CD4+ 
and CD8+ T cells in the peritoneal lavage shown in Figure 6B. (F) Peritoneal lavage FACS dot plots of 
adoptively transferred CFSE-labeled activated CD4+ T cells, which are representative of the analyses 
shown in Figure 6C. Data is representative of three (A, B, D, E) and two (C, F) separate experiments. 
(A-C) Values denote mean ± s.e.m, n=3 (biological replicates). *P<0.05; **P<0.01; ***P<0.001. 
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6 DISCUSSION AND FUTURE DIRECTIONS 
 
Chronic inflammatory diseases (CIDs) are a major public health concern in the 
western world. The non-resolving nature of inflammation in CIDs, associated with 
excessive and inappropriate activation of the immune system is critical for the 
disease process, yet some of the underlying cellular and molecular mechanisms 
have so far remained elusive. In this thesis, I have investigated the effect of lactate 
and the role of some major metabolic pathways in the regulation of T cell migration 
and functions in inflammation. Overall, I can draw four major conclusions of the 
above data that I will discuss in the context of recent literature. 
 
 
6.1 LACTATE INHIBITS T CELL MIGRATION 
	  
Initially, I could show that the presence of 10mM extracellular sodium lactate or 
lactic acid inhibits the migration of CD4+ and CD8+ T cells, respectively, to a pro-
inflammatory chemokine (Figure 1). This inhibition is mediated via two different 
short monocarboxylate transporters that are selectively expressed on each subset, 
which is a previously unknown difference. 
 
The described transporters mediate the uptake of lactate, which then acts as a 
potent inhibitor of glycolysis affecting a number of mediators, including the rate 
limiting glycolytic enzyme phosphofructokinase (PFK) (Leite et al., 2011). 
Intriguingly, I found that the inhibition of glycolysis represents the underlying 
mechanism for the observed reduction in T cell migration. This finding is in line with 
a report that shows the critical involvement of the glycolytic activator Pfkfb3 in the 
reorganization of the cytoskeleton in endothelial cells (EC) (De Bock et al., 2013). 
Loss of PFKFB3 caused a decrease in proliferation and migration of ECs, necessary 
for the formation of filopodia and lamellipodia and subsequent vessel sprouting. In 
a further report the group could show that targeted glycolytic reduction via small 
molecule blockage of PFKFB3 resulted in reduced vessel sprouting in EC spheroids, 
zebrafish and murine retina, arguing for a widespread glycolytic control of cell 
migration (Schoors et al., 2015). Support for this hypothesis comes from the 
finding that reduced expression of the 11Beta-hydroxysteroid dehydrogenase type 
1 (11βHSD1) mediates the induction of cell migration, invasion and angiogenesis 
via activation of glucose uptake and flux in hepatocellular carcinoma (HCC) (Liu et 
al., 2015). These findings stand in stark contrast to a previous report, showing that 
colorectal cancer cells rely on PGC1α dependent mitochondrial biogenesis, 
respiration and oxygen consumption for enhanced cell motility and cancer 
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invasiveness (LeBleu et al., 2014). Interestingly, using the small molecule 
Gamitrinib, Caino et.al (2013) could show that inhibition of the mitochondrial heat 
shock protein 90 (HSP90, TRAP1) also effectively reduced the migration of tumor 
cells (Caino et al., 2013). The inhibition or shRNA-mediated silencing of Tnf 
receptor associated protein 1 (TRAP1) resulted in a decrease in ATP levels and 
subsequent activation of AMPK, similar to the effects I had observed in CD4+ T cells 
exposed to sodium lactate (Figure 5E and 5F). The phosphorylation of AMPK led to 
an inhibition of Focal adhesion kinase (FAK) and consequently disruption of Rho-
Rac-Cdc42 mediated cytoskeletal rearrangement and cell migration. Contrarily to 
my findings in activated T cells treated with metformin (Figure 8A - 8C), 
constitutive active AMPK reduced tumor cell migration and metastasis in a mouse 
model of cancer metastasis (Caino et al., 2013). It is interesting to notice that in 
naïve T cells metformin had the opposite effect compared to activated T cells, 
pointing towards different metabolic requirements for cell migration or regulation 
thereof, possibly converging at AMPK, a master regulator for cellular homeostasis 
(Figure 8D; Wang and Green, 2012). More contradicting findings of AMPK 
promoting (Yan et al., 2015) or inhibiting cell migration (Nakano et al., 2010) 
possibly reflect the complexity of metabolic control of migration that is very likely 
cell type- and context-dependent and can be regulated by a wide variety of signals 
and effector molecules. 
 
To establish a causative link between lactate and inhibition of CXCL10 induced 
chemotaxis, I investigated the involvement of the observed LDH coupled change in 
NAD+ / NADH ratio (Figure 4A). The two major family representatives of NAD 
dependent enzymes Sirt1 and Parp1 are known to regulate cell migration, besides 
their role in controlling metabolic homeostasis (Cavone et al., 2011; Tang, 2010; 
Zhang et al., 2009). Interestingly, I could find that inhibition of either Sirt1 or 
Parp1 in the presence of sodium lactate could normalize the levels of chemotaxis 
towards CXCL10, yet had no effect on their own (Figure 8H). This finding suggests 
a lactate induced over activation and cross talk or competition for NAD+ between 
Sirt1 and Parp1 in the regulation of migration (Fang et al., 2014). Strikingly, this 
hypothesis fits very well with a report that investigated the role of PARP1 in the 
developing Drosophila eye. Uchida et al. (2002) could demonstrate that transgenic 
flies overexpressing Parp1 showed a disturbance of tissue polarity due to a 
disruption of the F-actin cytoskeleton, a phenotype that strongly resembles the loss 
of function phenotype of the small GTPase RhoA (Strutt et al., 1997). They went on 
to identify a genetic interaction between RhoA and Parp1 in which co-
overexpression of RhoA and Parp1 could partially rescue the observed effect of 
cytoskeletal disruption (Uchida et al., 2002). It will be interesting to investigate the 
exact mechanism of lactate mediated inhibition of CD4+ T cell migration, the 
89 / 123 
	  
relative contribution of metabolism and the molecular interactions of metabolic 
mediators with the cytoskeleton. It will be worth investigating the relative effects of 
lactate on mTORC2 signaling, which has been shown in neutrophils to control cell 
migration (Liu, 2010). The authors hereby describe a novel signaling network, in 
which mTORC2 regulates the production of cAMP through Adenyl cyclase AC9 and 
PKC. Production of cAMP in turn controls the activity RhoA GTPase, phosphorylation 
of myosin II at the rear end of the cell. Consequently, neutrophils inhibited in 
mTORC2 via knockdown of Rictor, show decreased ability of chemokine-induced 
cAMP production, cell polarization and rear end retraction. Interestingly, the 
authors could confirm that this effect was independent of actin polarization (Liu, 
2010). 
 
From the above data and reports it seems plausible that a cell uses various 
metabolic and molecular pathways to achieve migration that possibly depend on 
biochemical feasibility and the extracellular environment. 
 
 
6.2 LACTATE CHANGES T CELL FUNCTION 
 
As T cells are likely to be exposed to lactate as a consequence of activation and 
proliferation in the lymph node during an immune response (Buck et al., 2015), it is 
possible that the expression of either transporter determines the functional 
differentiation of T cell subsets (Sinclair et al., 2013). The physiological significance 
of this distinct transporter expression by activated CD4+ and CD8+ T cells might 
dictate their functional responses depending on the nature of the inflammatory 
exudate. As I could show in Figure 3 the presence of 10mM lactic acid or sodium 
lactate inhibits the cytolytic activity of CD8+ T cells and induces the production of 
IL-17 in CD4+ T cells, respectively. The observed inhibition of cytotoxicity in CD8+ 
CTLs by lactic acid has previously been demonstrated by Fischer et al (2007), 
(Figure 3D). Interestingly, besides the inhibition of cytotoxicity that was due to a 
reduction in intracellular Perforin and Granzyme B abundance, also IL-2 and IFNγ 
production as well as proliferation was diminished. Importantly, these reductions 
were not due to a drop in pH conferred by the addition of lactic acid in the media, 
but the protons were required for lactate uptake in a MCT1-dependent manner 
(Fischer et al., 2007). As extracellular lactate is an inducer of hypoxia (De 
Saedeleer et al., 2012; Sonveaux et al., 2008), it is noteworthy that a recently 
published report describes the requirement of HIF1α in the expression of perforin in 
CTLs (Finlay et al., 2012). Although not directly investigated, it seems thus likely that 
the lactate-mediated reduction of CTL cytotoxicity is independent of hypoxia and Hif1α. 
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In the CD4+ T cell subset, the exposure to 10mM sodium lactate induced the 
production of the cytokine IL-17 – associated to many inflammatory conditions - in 
all differentiation states (Figure 3A and 3B). These cells acquire a mixed phenotype 
whereby they continue to express their own signature cytokines but at the same 
time increase the transcription of RORγT and IL-17. In this context, it has recently 
been suggested that increased sodium chloride (NaCl) concentrations found locally 
under physiological conditions in vivo markedly boost the induction of murine and 
human Th17 cells in autoimmune conditions (Kleinewietfeld et al., 2013). The 
authors could show that elevated levels of NaCl stimulated the phosphorylation of 
p38 / Mapk, a known hypertonic stress response element, with concomitant 
activation of Nfat5 and its downstream target serum / glucocorticoid kinase 1 
(Sgk1). Knockdown of either Sgk1 or Nfat5, or pharmacological inhibition of Sgk1, 
Nfat5 or p38 normalized the NaCl induced expression of IL-17 in vitro and in vivo. 
Interestingly, the Na+ cation could be demonstrated to be responsible for the 
observed effect. These findings align with those reported by another group, which 
also found SGK1 as essential downstream effector of IL-23 signaling during the 
differentiation of Th17 cells (Wu et al., 2013). Using IL-17fCreSgk1fl/fl knockout 
mice, in which SGK1 is specifically deleted in IL-17 producing CD4+ T cells, the 
authors could show that the kinase does not affect primary Th17 differentiation, but 
rather affects their stability, provided by IL-23 signaling. Contrarily to both groups, 
which have used naïve CD4+T cells, I have analyzed memory T cells already 
committed to a specific subset, similar to T cells in the inflammatory site and 
exposed them to another kind of salt – sodium lactate. Although not directly 
investigated, I found that the lactate ion rather than the sodium ion exerted the IL-
17 induction via a LDH dependent mechanism (Figure 10B). 
 
Lactate is known to inhibit glycolysis, at least in part via interaction with Pfk (Leite 
et al., 2011), yet glycolysis has been shown to be important for the differentiation 
of Th17 cells (Shi et al., 2011). Interestingly, both inhibition of glycolysis via 2-DG 
and Rapamycin, as well as activation via metformin could increase the secretion of 
IL-17 in activated, non-differentiated CD4+ T cells (Figure 10A). Contrarily, the 
mRNA levels in these conditions did not change, which points towards a 
posttranscriptional mechanism that is independent to the sodium lactate mediated 
IL-17 induction. In line with this hypothesis, Noubade et al (2014) could show a 
posttranscriptional mechanism of IL-17 production that is mediated via the p38 / 
Mapk pathway, which is likely to represent the same stress pathway described 
earlier with NaCl (Kleinewietfeld et al., 2013; Wu et al., 2013). It seems thus 
plausible that the IL-17 production due to exposure of 2-DG, Rapamycin or 
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metformin is not mechanistically connected with the observed effect of sodium 
lactate, nor is it a direct consequence of glycolytic inhibition or activation. 
 
Blocking glycolysis via the LDH inhibitor oxamate, however, could induce IL-17 
mRNA synthesis to similar levels as those observed with sodium lactate, yet it 
rescued its sodium lactate dependent generation (Figure 10B). The LDH catalyzes 
the reduction of pyruvate to lactate with concomitant oxidation of NADH to NAD+ 
when pyruvate is abundant or the generation of pyruvate when lactate is abundant. 
Downstream effector enzymes of NAD+ include the histone deacetylase Sirt1 as well 
as the Poly-(ADP-Ribose) polymerase Parp1 (Chung and Joe, 2014). My results 
show that the inhibition of Sirt1 or Parp1 could reverse the effect of sodium lactate 
(Figure 10B), suggesting that decreased Parp1 activity is responsible for the 
transcription of IL-17. In line with this conclusion, Rutz et al (2015) found that 
inhibition of Parp1 with the small molecule Veliparib could increase the production 
of IL-17 in murine Th17 cells. Of note, the authors also showed an increase in Rorc 
and Il17 mRNA, similar to the results I obtained with sodium lactate treatment 
(Figure 3). They further identified a Deubiquitinase DUBA – UBR5 dependent 
ubiquitinilation of RorγT that serves as a posttranscriptional break on IL-17 
transcription (Rutz et al., 2015). The posttranslational regulation of IL-17 has 
recently received a lot of attention. Lim et al, (2015) show that the deacetylase 
Sirt1 promotes autoimmunity by deacetylating RorγT, which leads to the generation 
of Th17 cells and enhanced production of IL-17 cytokine. They found that Sirt1 
physically binds to the C-terminal domain of RORγT and deacetylates three lysine 
residues in its DNA binding region, thereby enhancing its transcriptional activity. In 
a mouse model of experimental autoimmune encephalomyelitis (EAE), Sirt1 
knockout mice or the inhibition of Sirt1 with the small molecule Ex-527 could 
protect the mice from the disease (Lim et al., 2015). In this context it is interesting 
to notice, that the inhibition of Sirt1 also normalized the IL-17 levels (Figure 10B). 
It seems thus likely that again Parp1 and Sirt1 act in an antagonistic crosstalk, 
whereby the inhibition of Parp1 is the crucial act that leads to IL-17 production 
(Chung and Joe, 2014; Rutz et al., 2015). 
 
Besides the involvement of Parp1, I could also show that inhibition of Foxo1, a 
major transcription factor that controls cellular metabolism and has been implicated 
in Th17 cell differentiation (Laine et al., 2015; Ouyang et al., 2010), could 
normalize the levels of IL-17 mRNA upon lactate exposure. In contrast to my 
observations, Laine et al (2015) and Ouyang et al (2010) described FOXO1 as a 
negative regulator for Th17 differentiation. This discrepancy could be explained by 
the fact that the FOXO proteins function in response to environmental stimuli in 
order to ensure homeostasis (Eijkelenboom and Burgering, 2013). As the treatment 
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with sodium lactate represents a change in the cells’ microenvironment, it seems 
plausible that also Foxo1 activity might adapt towards re-establishing homeostatic 
conditions. Similarly, I found that HIF1α, the major cellular response element to 
changes in environmental oxygen concentration, is not - or only partly - involved in 
the pathway that leads to the induction of IL-17 in response to lactate (Figure 10B). 
This finding is surprising, as both lactate is known to induce a state of pseudo-
hypoxia (De Saedeleer et al., 2012; Sonveaux et al., 2008) and Hif1α has been 
shown to regulate Th17 differentiation in a variety of ways (Dang et al., 2011; Shi 
et al., 2011; Wang et al., 2014). Induction of hypoxia via DFO but not CoCl2 could 
raise Il17 mRNA levels in a similar way to sodium lactate and inhibition of Hif1α 
with TOFA but not C75 could inhibit Il17 expression in presence of sodium lactate 
(Figure 10B). Interestingly, TOFA is an inhibitor for ACC, the rate limiting enzyme 
of fatty acid synthesis (Donaldson, 1979), which has been shown to be important 
for the generation of Th17 cells (Berod et al., 2014). 
 
In conclusion, the exact mechanism by which sodium lactate induces the 
transcription of Il17 is not yet fully decoded, but I could show so far that it involves 
NAD metabolism via inhibition of PARP1 (Figure 6), FOXO1 activity and FAS. It will 
be interesting to investigate both transcriptional and potential post-translational 
effects that mediate the production of IL-17 in response to enriched lactate levels. 
The discrepancies between findings involving FOXO1 and HIF1α as regulator of 
Th17 cell differentiation are likely to reflect alternative adaption mechanisms to a 




6.3 LACTATE CAUSES METABOLIC INHIBITION AND ADAPTION 
 
Lactate has been shown to have a variety of effects on cellular metabolism, 
including the inhibition of glycolysis (Berg et al., 2002)the increase of mitochondrial 
oxphos in neurons (Magistretti et al., 1994; Tarczyluk et al., 2013), the induction of 
gluconeogenesis during the Cori cycle in the liver  and the synthesis of glycogen in 
skeletal muscle cells (Cornell et al., 1973). Consistent with these reports, I 
observed a drastic decrease in glycolytic flux within the first 10 minutes after 
exposure to lactate, an indication for regulation at the level of enzyme activity 
(Zhao and Qu, 2009). This is in line with a previously described feedback inhibition 
of glycolysis by direct interaction of lactate with PFK, a rate-limiting enzyme of the 
glycolytic pathway (Leite et al., 2011). Interestingly, also the levels of oxidized NAD 
dropped within the first 10 minutes of lactate treatment, which is most likely due to 
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the reversal of the LDH reaction (Figure 4A, Equation 1). NAD+ is used as an 
essential cofactor for the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
reaction that catalyzes the conversion of D-glyceraldehyde 3-phosphate to 1,3-
bisphosphoglycerate. It remains an open question which of the proposed 
mechanisms of glycolytic inhibition is in play in CD4+ T cells, if both are occurring 
simultaneously or even additional ways of inhibition exist (Williamson, 1965). 
 
Interestingly though, the initial reduction of NAD+ to NADH 10 minutes after lactate 
exposure was followed by a decrease in NADH levels at 30 and 60 minutes that was 
not due to re-oxidation to NAD+, suggesting its possible utilization by the electron 
transport chain (Ying, 2008) (Berg, 2002). In line with this hypothesis, the levels of 
reactive oxygen species (ROS) in whole cell extracts 20 and 30 minutes after 
lactate exposure were increased (Figure 4B). Surprisingly, ROS levels also 
displayed an early increase after 5 minutes of lactate treatment. In this context, a 
recent report describes the identification of a putative flavin-dependent lactate 
oxidase in the intermembrane space of hepatic mitochondria (de Bari et al., 2010). 
The authors could demonstrate that lactate exposure to isolated mitochondria 
produced pyruvate in a 1:1 stoichiometry with the concomitant release of H2O2 that 
was independent from the respiratory chain. It is possible that a similar mechanism 
also led to the transient increase in ROS levels in CD4+ T cells.  
 
Mitochondrial ROS results from stepwise reduction of O2 as a secondary product of 
the ETC, and acts as a signaling molecule in a variety of cellular responses 
(Chouchani et al., 2014; Murphy, 2009; Okoye et al., 2015; Sena et al., 2013). It 
is thus interesting to note that although lactate has been shown to be able to act as 
a fuel for oxidative metabolism (Magistretti et al., 1994; Tarczyluk et al., 2013) and 
to increase ROS production, CD4+ T cell mitochondrial activity and ATP levels 
decreased after exposure to lactate (Figure 5D ad 5E). 
 
The LDH dependent oxidation of lactate yields pyruvate, which can then enter the 
TCA cycle after being converted to acetyl-CoA. I indeed found levels of acetyl-CoA 
enriched 2-fold between 10 and 60 minutes after lactate treatment (Figure 4C). 
More strikingly, citrate levels were increased up to 8 fold (Figure 4D). An 
accumulation of citrate and succinate was recently reported during the 
differentiation of classically activated (M1-like) macrophages using an integrated 
high-throughput transcriptional-metabolic profiling approach (Jha et al., 2015). The 
authors identified a break of the TCA cycle after Isocitrate dehydrogenase (IDH), 
which converts isocitrate to α-ketoglutarate and was responsible for the citrate 
accumulation. In macrophages citrate can be used for the production of the 
antimicrobial agent itaconic acid or for the synthesis of fatty acids, a hallmark of M1 
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polarization (Infantino et al., 2011). Interestingly, after lactate treatment I also 
detected activation of the rate limiting enzyme for fatty acid synthesis acetyl-CoA 
Carboxylase (ACC) (Figure 5F), which has been shown to be indispensable for IL-17 
production in CD4+ T cells (Berod et al., 2014). Moreover, citrate is a known 
inhibitor of glycolysis and its accumulation might be responsible for the prolonged 
glycolysis inhibition observed (Newsholme et al., 1977; Williamson, 1965).  
 
Surprisingly though, I found that the glycolytic activity normalized 4 hours after 
exposure to lactate (Figure 9C). In conjunction with the increased mitochondrial 
localization of HK1 at this time point (Figure 9A and 9B) this might reflect a 
metabolic adaption to rescue the glycolytic flux and ATP production (Calmettes et 
al., 2013). The localization of Hexokinases to the mitochondrial membrane is a 
widespread adaptive phenomenon in response to energy depletion. It is proposed 
to directly expose the enzymes to newly formed ATP from the mitochondria and 
thereby rescue the glycolytic flux in the cytoplasm. More in depth investigation is 
necessary to elucidate other metabolic pathways affected by the presence of 
lactate, adaption mechanisms and their consequences, and whether interference 
with these are able to reproduce or rescue some of the cellular effects observed 
(Berod et al., 2014; Uchida et al., 2002). Moreover, a broad scale metabolic 
analysis would also be able to reveal, whether lactate exposure could cause a break 
in the TCA cycle leading to citrate and succinate accumulation that is responsible 
for the reported cellular consequences. 
A working model for the intracellular signaling pathways is presented in Figure 13. 
 
 
6.4 LACTATE SIGNALING PERPETUATES CHRONIC INFLAMMATION 
 
The phenotype of T cells exposed to lactate recapitulates key features of T-
lymphocytes found in chronic inflammatory infiltrates, including their entrapment, 
the production of high levels of IL-17 production by CD4+ T cells and loss of 
cytolytic activity in CD8+ T cells (Figure 14A) (Gerriets and Rathmell, 2012; Haas et 
al., 2013). I could show that sodium lactate induces all CD4+ Th subsets to increase 
their production of the pro-inflammatory cytokine IL-17 via a not yet completely 
elucidated mechanism, which is prevalent in the inflamed tissue and is known to 
drive forward the chronic inflammatory process in many CIDs (Gerriets and 
Rathmell, 2012; Haas et al., 2013). I hence tested the significance of lactate 
signaling in a disease model of chronic inflammation by investigating human 
samples of rheumatoid arthritis. In keeping with the in vitro data, I found that in 
chronically inflamed synovial tissue, a disease associated with high levels of IL-
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17+/CD4+ T cells in the joints (Chabaud et al., 1999), infiltrating CD4+ but not CD8+ 
T cells almost invariably displayed high expression of the lactate transporter 
SLC5A12. This suggests that the expression of SLC5A12on the CD4+ subset may be 
involved in the entrapment of CD4+ T cells within the chronically inflamed “milieu” 
of the RA synovium (Figure 14A). I could further demonstrate that targeting the 
lactate transporters SLC16A1 and SLC5A12re-establish T cell migration to 
consequently release them from the inflammatory site and block the production of 
IL-17, with potential therapeutic implications in the management of CIDs (Figure 
13B). In this context, it has been shown that the neutralization of IL-17 protein in a 
mouse model of Collagen induced arthritis (CIA) could reduce joint inflammation, 
cartilage destruction and bone erosion (Lubberts et al., 2004). In rheumatoid 
arthritis a combined treatment of dual cytokine inhibition (IL-17 and TNFα) shows 
greater potential than single neutralization itself (Buckland, 2014; Fischer et al., 
2015). In light of this, interference of lactate signaling in RA by inhibition of the two 
identified transporters paves the way for additional therapeutic approaches. 
Hereby, targeting not only the production of IL-17, but also the entrapment of T 
cells in the inflamed site represents a potential treatment for two independent 
mechanisms of disease progression (Al-Saadany, 2015; Haas et al., 2013). It 
should be borne in mind, however, that the effect of IL-17 in other models of 
chronic inflammation is however still controversial, as IL-17A or IL-17F gene 
knockout in a model of autoimmune neuro-inflammation did not alter any of the 
pathological signs (Haak et al., 2009). 
 
Additional evidence has to be generated to define the functional effects of Slc16a1 
inhibition on the CD8+ T cell subset in CIDs. Interestingly, the role of CD8+ T cells 
in RA is not completely understood. On the one hand, activated CD8+ T cells 
express high levels of the pro-inflammatory cytokines IFNγ and TNFα that drive RA 
associated pathologies and have been shown to regulate the structural integrity of 
the synovial membrane (Kang et al., 2002; Wagner et al., 1998). On the other 
hand, RA is often associated with persistent viral infections that inversely correlate 
with the function of virus-specific CD8+ T cells in the synovial fluid and worsened 
disease outcome (Croia et al., 2013). In this context, the presence of enhanced 
lactate levels in the inflamed synovial fluid is likely to impact some of the CD8+T 
cell-mediated pathological features of RA and represents another interesting target 
for therapeutic intervention. 
 
In summary, my observations suggest that lactate signaling in the inflammatory 
“milieu” may promote some of the pathogenic features and persistence of the T cell 
infiltrates. Importantly, I show that pharmacologic targeting of lactate transporters 
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in T cells might provide a novel approach to resolve chronic T cell-mediated 
inflammation in CIDs. 
 
 
6.5 FUTURE DIRECTIONS 
 
Although in this thesis I could shed some light on novel aspects of lactate signaling 
in chronic inflammation, several key questions remain unanswered that should be 
addressed in the future. 
 
I could demonstrate, that the effect of extracellular lactate on T cell migration and 
function is mediated via transmembrane transporters, selectively expressed on 
CD4+ and CD8+ T cell subsets (Figure 2). However, the actual uptake of lactate in T 
cells has not been assessed. The most common techniques to measure direct 
uptake of a metabolite by a cell includes treatment with a radioactive isotope and 
subsequent determination of intracellular radioactivity in a cell lysate, as could be 
achieved with L-(U-14C) lactate. Another, more detailed method includes the use of 
a stable isotope with one or more 13C atoms in conjunction with either mass 
spectrometry or nuclear magnetic resonance spectroscopy to delineate the specific 
intracellular fate of lactate. This technique would provide important mechanistic 
insights of lactate action. 
 
Additionally it will be important to determine the overall intracellular signaling 
network of lactate, including the investigation and biochemical characterization of 
lactate transporters and other lactate utilizing enzymes in the different subcellular 
compartments (Schueren et al., 2014; de Bari et al., 2010) of CD4+ and CD8+ T 
cells. To substantiate the findings of this thesis, this characterization should also 
include a more detailed description of the effect of pH on the species of lactate 
present in inflammatory exudates. I used unbuffered and bicarbonate buffered 
growth media to separate the effect of pH from that of the lactate anion (Figure 1). 
Nevertheless, accurate pH measurements of synovial fluid and determination of its 
buffering capacity, will deliver potent pathophysiological relevance to the findings. 
 
Lactate is only one of the factors in the inflammatory microenvironment that could 
influence the function of infiltrating immune cells. It is therefore important to 
approach this problem from a systems biology perspective and identify other 
soluble and cellular factors that could potentially interfere with the course of the 
immune response. Abundance of soluble factors from inflammatory sites can be 
measured by using for instance non-targeted mass spectrometry analysis, which 
would allow for an accurate reconstruction of the microenvironment. This will 
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consequently allow for the identification of the dominant factors that influence T cell 









Figure 13 Suggested working model for intracellular lactate signaling in T 
cells. 
Schematic of the suggested time dependent mechanism of intracellular lactate signaling in T-cells  




Figure 14 Schematic depiction of the influence of lactate on T cells in the 
inflammatory site and the effects of lactate transporter inhibition  
Schematic of the proposed mechanism of lactate effects on T-cells in the inflammatory site. (A) The 
motility of CD4+ and CD8+ T-cells is blocked once they get exposed to elevated levels of sodium-
lactate and lactic acid, respectively, in the inflammatory site. Lactic acid also causes CD8+ T-cells to 
lose their cytolytic activity and sodium-lactate causes CD4+ T-cells to increase their production of IL-
17. (B) Anti- lactate transporter antibodies re-establish T-cell migration away from the inflammatory 
site and block the production of high amounts of IL-17.  
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Age (range) 46-76 
Gender (%)  
   Female 80 
   Male 20 
Site (%)  
   Large joint 68 
   Small joint 32 
Erosive (%) 63 
Treatment (%)  
   DMARDs 81 
  Steroids 15 
  Biologics 61 
RF+ and/or CCP+ (%) 67 
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Table 2 List of used qPCR Primers 
Primer name Sequence Species Description 
Slc16a1_F GCTGGAGGTCCTATCAGCAG mouse Monocaboxylic acid transporter 1 
Slc16a1_R AGTTGAAAGCAAGCCCAAGA mouse Monocaboxylic acid transporter 1 
Slc5a12_F AAGCACCTATGAGTACTTACAGC mouse sodium-coupled monocarboxylate transporter 2 isoform 1 
Slc5a12_R ACCAGTCACTTGGTTGAGAGC mouse sodium-coupled monocarboxylate transporter 2 isoform 1 
Hk1_F AAAGCGGTTCAAAGCCAGTG mouse hexokinase-1 isoform HK1 
Hk1_R CACCACAGCTACAATGTTAGCG mouse hexokinase-1 isoform HK1 
PkM2_F CCACTTGCAATTATTTGAGGAA mouse Pyruvate Kinase M2 Isoform 
PkM2_R GTGAGCAGACCTGCCAGACT mouse Pyruvate Kinase M2 Isoform 
Glut1_F CACTGTGGTGTCGCTGTTTG mouse Slc2a1 solute carrier family 2, member 1 
Glut1_R ATGGAATAGGACCAGGGCCT mouse Slc2a1 solute carrier family 2, member 1 
Glut2_F GGAAGTCAGGGCAAAGAAAAGC mouse Slc2a2 solute carrier family 2, member 2 
Glut2_R AATTGGCATCCGTGAAGAGC mouse Slc2a2 solute carrier family 2, member 2 
Glut3_F AACTTGCTGGCCATCATTGC mouse Slc2a3 solute carrier family 2, member 3 
Glut3_R TGCACAGGCCACAGAAAATG mouse Slc2a3 solute carrier family 2, member 3 
Glut4_F TGGCCTTCTTTGAGATTGGC mouse Slc2a4 solute carrier family 2, member 4 
Glut4_R AACCCATGCCGACAATGAAG mouse Slc2a4 solute carrier family 2, member 4 
Pck1_F TCGGGAAGAAATGCTTTGCG mouse phosphoenolpyruvate carboxykinase, cytosolic [GTP] 
Pck1_R TATGCCCAGGATCAGCATATGC mouse phosphoenolpyruvate carboxykinase, cytosolic [GTP] 
Pck2_F CCTGGAAACCTGGTGACAAGG mouse phosphoenolpyruvate carboxykinase [GTP], mitochondrial 
Pck2_R CTGCTCCCAGAAGTCCTTGG mouse phosphoenolpyruvate carboxykinase [GTP], mitochondrial 
Fbp1_F AAAGCCCAAGTGGAAAGCTG mouse Fructose-1,6-Bisphosphatase 1 
Fbp1_R ATATCTTTGTCCCCCGTGGTG mouse Fructose-1,6-Bisphosphatase 1 
Pgc-1a_F CTCTGGAACTGCAGGCCTAAC mouse peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
Pgc-1a_R CCTTTCTTGGTGGAGTGGCT mouse peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
Ppara AGCTCACAGAATTTGCCAAG mouse peroxisome proliferator-activated receptor alpha 
Ppara TTCCATGATGTCACAGAACG mouse peroxisome proliferator-activated receptor alpha 
G6Pc_F AGCTGAACGTCTGTCTGTCC mouse glucose-6-phosphatase, catalytic subunit 
G6Pc_R TTCTCCAAAGTCCACAGGAG mouse glucose-6-phosphatase, catalytic subunit 
Lta_F / TNF-B_F TGTGTTCCTGCTCAGTAAGGG mouse lymphotoxin-alpha precursor (TNFbeta) 
Lta_R / TNF-B_R ACAGTGCAAAGGCTCCAAAG mouse lymphotoxin-alpha precursor (TNFbeta) 
IL4_F TCGGCATTTTGAACGAGGTC mouse interleukin-4 precursor 
IL4_R TGGTGTTCTTCGTTGCTGTG mouse interleukin-4 precursor 
IL5_F CCGCCAAAAAGAGAAGTGTGG mouse interleukin-5 precursor 
IL5_R TTCCATTGCCCACTCTGTACTC mouse interleukin-5 precursor 
IFNg_F ATCAGGCCATCAGCAACAAC mouse Interferon gamma precursor 
IFNg_R TGCATCCTTTTTCGCCTTGC mouse Interferon gamma precursor 
IL13_F ATTGCATGGCCTCTGTAACC mouse interleukin-13 precursor 
IL13_R GGCGAAACAGTTGCTTTGTG mouse interleukin-13 precursor 
IL-17_F AAAGCTCAGCGTGTCCAAAC mouse interleukin-17A precursor 
IL-17_R TTCTGGAGCTCACTTTTGCG mouse interleukin-17A precursor 
Rorc_F TCAAGTTTGGCCGAATGTCC mouse RAR-related orphan receptor gamma 
Rorc_R ACTTGTTCCTGTTGCTGCTG mouse RAR-related orphan receptor gamma 
SLC16A1_F CACCCACAGAGGCTTTTTGC human monocarboxylate transporter 1 
SLC16A1_R GTCGGGCTACCATGTCAACA human monocarboxylate transporter 1 
SLC5A12_F GTGTGCTGTCTTCTCTGGCT human sodium-coupled monocarboxylate transporter 2 
SLC5A12_R GCCACAAAAAGTCCTGGCAG human sodium-coupled monocarboxylate transporter 2 
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Table 3 List of used Buffers 
Buffer Composition         
Cell Lysis Buffer 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 
 
RIPA 
50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL CA-630, 1% sodium deoxycholate, 0.1% 
SDS 
Laemmli 0.1% 2-Mercaptoethanol, 0.0005% Bromophenol blue, 10% Glycerol, 2% SDS, 63 mM Tris-HCl, (pH 6.8) 
2x BBS 50 mM BES (N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid), 1.5 mM Na2HPO4, 280mM NaCl 
Fixation Buffer 2% paraformaldehyde in 1xPBS 
   
Permeabilization buffer 0.1% Triton X-100 in 1xPBS 
   
FACS buffer 0.5% BSA , 0.05% Azide in 1xPBS 
   
Cell Isolation Buffer 2% FBS, 10mM EDTA in 1xPBS 
 	   	  
TBST 0.1% Tween 20 in 1x Tris buffered Saline 
	   	  
Milk 5% non-fat dry milk in 1x TBST 
	   	   	   
 
Table 4 List of used antibodies 
Antibody Clone Source Producer 
CD3 17A2 rabbit Biolegend 
CD28 37.51 rabbit Biolegend 
CD3 Hit3a rabbit Biolegend 
CD28 28.2 rabbit Biolegend 
  
   
Slc5a12 ab107749 rabbit Abcam 
Slc16a1 ab90582 rabbit Abcam 
Hexokinase 1 C35C4 rabbit Cell Signalling 
Pyruvate Kinase M1/2 C5E6 rabbit Cell Signalling 
Aldolase A D73H4 rabbit Cell Signalling 
Enolase 1 D2S1A rabbit Cell Signalling 
Pyruvate Dehydrogenase C54G1 rabbit Cell Signalling 
Acetyl-Lysine Ac-K-103 rabbit Cell Signalling 
pAMP Kinase α D5A2 rabbit Cell Signalling 
total AMP Kinase α 40H9 rabbit Cell Signalling 
pAcetyl CoA Carboxylase D7D11 rabbit Cell Signalling 
total Acetyl CoA Carboxylase C83B10 rabbit Cell Signalling 
Poly (ADP-Ribose) polymerase 1 10H rabbit Adipogen 
Histone H3 3H1 rabbit Cell Signalling 
β-Actin 1,30E+06 rabbit Cell Signalling 
  
   
CD4 RPA-T4 rabbit Biolegend 
IL17A BL168 rabbit Biolegend 
Slc5a12 NBP1-92408 rabbit Novus Biologicals 
  
   
CD3 17A2 rabbit ebioscience 
CD4 GK1.5 rabbit ebioscience 
CD8 SK1 rabbit ebioscience 
CD25 3C7 rabbit ebioscience 
CXCR3 CXCR3-173 rabbit ebioscience 
CCR7 4B12 rabbit ebioscience 
CD62L MEL-14 rabbit ebioscience 
LFA-1 YN1/1.7.4 rabbit ebioscience 
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